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Abstract
With more than 20 million cases worldwide, Alzheimer’s disease (AD) is now the most 
common neurodegenerative disease. The two defining features of this disease are 
extracellular plaques and intracellular neurofibrillary tangles.
Although no AD treatment is available, researchers are making encouraging progress, 
including the use of small compounds which interact with amyloid-p (AP) and affect its 
self aggregation. Tetracyclines (TCs) are thought to have an anti-amyloidogenic effect on 
Ap peptides. But the inconsistency of results in literature prompted us to further investigate 
the behaviour of various fragments of Ap (Apl-40; Apl-42; guest-host-peptide Ap 14-24) 
which were synthesised as depsi-peptides, in the presence of TCs. Due to their superior 
solubility the depsi-peptides allowed us to prepare reliable and seed-free stock solutions 
with reproducible properties. These allowed the preparation of different well-characterised 
Api-42 species (initial state, oligomers, and fibrils), and to investigate the binding of Ap 
ligands (Ap monomers or TCs) to them or to study the modulation of the kinetics of fibril 
formation in the absence or presence of TCs, by Surface Plasmon Resonance (SPR), 
Circular Dichroism (CD) or Thioflavine-T (ThT) fluorescence.
Binding of Api-42 monomers to immobilised fibrils could be well described by the “Dock 
and Lock” mechanism. TCs do not bind to the prepared Ap species nor do they alter the 
highly reproducible kinetics of fibril formation or disaggregated preformed amyloidogenic 
structures. Consistent with the inactivity of TCs against amyloid p-sheet structures the 
treatment of APP/PSltg mice with doxycycline (DC) after plaque formation did not change 
the plaque load in this mouse model compared to the control mice. These findings suggest 
that toxic Ap species other than these considered in this study or the common 
neuroprotection seen for TCs might be responsible for the positive effects in-vivo in 
previously reported studies.
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1 Introduction
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Introduction
1.1 Misfolding diseases
A broad range of human diseases arises from the failure of a specific peptide or protein to 
adopt, or remain in, its native functional conformational state. The largest group of 
misfolding diseases, however, is associated with the conversion of specific peptides or 
proteins from their soluble states ultimately into highly organised fibrillar aggregates, but 
comprise many different proteins with no obvious sequence similarity (Chiti and Dobson, 
2006). These structures are generally described as amyloid fibrils or plaques when they 
accumulate extracellularly, whereas the term “intracellular inclusions” has been suggested 
when formed inside the cell.
A list of known neurodegenerative diseases that are associated with the formation of 
extracellular amyloid fibrils or intracellular inclusions with amyloid-like characteristics is 
given in Table 1-1, along with the specific proteins which are the predominant component 
of the deposits. They may be globular proteins with rigid 3D-structure or belong to the 
class of natively unfolded (or intrinsically unstructured) proteins (Uversky and Fink, 
2004). Despite these differences, the final fibrillar form of the different pathologies display 
many common properties including a core cross-P-sheet structure and there is an increasing 
belief that the capability to form fibril is a generic property of the peptide sequence (Chiti 
and Dobson, 2006).
Table 1-1: Amyloid related diseases (Chiti and Dobson, 2006)
Disease Involved protein
Alzheimer’s Disease 
Parkinson’s disease 
Creutzfeldt Jakob disease 
Huntington’s disease
Frontotemporal dementia with Parkinsonism 
Familial British dementia
Amyloid B-protein 
a-Synuclein
Prion protein and fragments 
Huntingtin 
Tau 
ABri
There are conflicting evidences for the role of the fibrillar amyloid found in the deposits, 
since it not always correlates with the pathology. That is why oligomeric fibril precursors
Introduction
are currently under investigation to establish their role in the progression of the diseases. 
These aggregates formed early in the aggregation process, have been reported in many 
different degenerative diseases. Other in-vitro formed stable aggregates different than 
fibrils and on-pathway oligomers are off-pathway oligomers and amorphous aggregates 
whose formation depends on the experimental conditions used.
1.1.1 Mechanism of fibril formation
Experimental studies have shown for a range of peptides and proteins that amyloid fibril 
formation is preceded by the appearance of organised assemblies usually termed 
protofibrils and smaller oligomeric species at yet earlier stages of the aggregation process. 
These oligomers appear initially to be relatively disordered, but then convert into species 
containing extensive p-sheet structure, that are often capable of stimulating fibril 
formation.
In the beginning the native monomeric structure of a protein is destabilised to form a 
partial folded state, which increases the population of non-native states prone to aggregate. 
This includes the unfolding of globular proteins to a partially unfolded state and the partial 
folding of native unstructured proteins like Alzheimer’s disease (AD) peptide fragments to 
a more aggregation prone state, which is governed by the amino acid sequence and by the 
details of the protein environment. But the characterization of fibril formation solely based 
on the partially unfolded states is unlikely to provide a detailed description of the 
mechanism of aggregation. Additionally, a high aggregation propensity of sequence could 
direct the aggregation, independent of the extent and stability of the non-persistent 
structure of an unstructured sequence.
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v  — 
seeded growth
lag Urn*
Fig. 1-1: Nucleation Polymerization A: The model B: The time dependant formation of fibrils with and 
without seeds (Harper and Lansbury, 1997).
Many of the polymerizing peptides are thought to follow a nucleation-dependent pathway 
(Harper and Lansbury, 1997), when the concentration of the solution is higher than the 
critical concentration. These processes are characterised by a slow nucleation phase the so 
called lag phase. During the lag phase the protein undergoes several unfavourable 
association steps of ordered monomers (nucleation barrier) to form an ordered oligomeric 
aggregate the nucleus. The initial phase is followed by the exponential growth phase, in 
which the nucleus rapidly grows to form larger assemblies until a plateau (steady state) is 
reached, in which the ordered aggregate and the monomer appear to be at equilibrium. If 
seeds are added during the lag phase or already present in the starting solution, the peptide 
polymerises immediately. Not all experimental results can be explained with nucleated 
polymerization (NP). Serio et. al. proposed a nucleated conformational change (NCC) 
mechanism for the polymerization of NM protein (NH2-terminal (N) and highly charged 
middle (M)) of the Sup35 prion protein (Serio et al., 2000). Monomeric NM possesses a 
high degree of conformational flexibility (random-structure) in aqueous buffers and is 
thought to coalesce into unordered “molten” aggregates in a first step, followed by 
reorganization to highly ordered oligomers.
4
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Nucleated Conformational Conversion (NCC)
Fig. 1-2: The nucleated conformational change (NCC) model (Serio et al., 2000).
The fibril formation is then continued by addition of unordered monomer or unordered
oligomers to the ordered nucleus. Unordered monomer addition, usually called “Dock and
lock” mechanism, was proposed to explain the growth of Ap and PrP 82-146 fibrils (Esler
et al., 2000; Gobbi et al., 2006; Nguyen et al., 2007). According to this idea, the attachment
of a monomer to ordered assembly is followed by a much slower and rate-limiting lock
phase (reorganization).
Auer et al. proposed a unifying framework , which was tested by computer simulations 
(Auer et al., 2009). They found that the interplay between highly directional hydrogen 
bonds and nonspecific hydrophobic interactions explains the observed two-step 
condensation-ordering mechanism which corresponds to NCC. This mechanism was 
favoured at higher peptide concentration which additionally lowered or even abolished the 
nucleation barrier. Interestingly, at low concentrations or weak hydrophobicity, the 
formation of fibrillar structures proceed via the formation of polypeptide chains, converted 
directly into P-sheet structures, which compares to the NP-mechanism.
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1.2 Alzheimer’s disease
Alzheimer’s disease (AD) is a devastating disease. The majority o f AD cases belong to the 
sporadic or late-onset form of AD, which tends to occur later in life. One in 20 people over 
65, and one in five over 85, have AD. Since the elderly population will increase three to 
four fold by 2050 in highly industrialised regions and the advancing age is the strongest 
risk factor to develop the disease, AD will result in a huge social and economic burden 
(Minati et al., 2009).
It is believed, that changes in the brain start decades before the symptoms. Although the 
course of Alzheimer’s disease is unique for every individual, there are many common 
symptoms. Most commonly recognised symptom is memory loss. This mild cognitive 
impairment (MCI) can be revealed up to eight years before AD is diagnosed, because the 
brain is still capable to compensate for the changes. After the diagnosis the patient goes 
through three different stages, mild, moderate, severe AD. During the progress of the 
disease, symptoms include confusion, irritability and aggression, mood swings, language 
difficulties, and long-term memory loss. Gradually, body functions are lost, which in the 
end leads to death by aspiration pneumonia, because a person is not able to swallow 
properly and takes food or liquids into the lungs instead of air.
Am nestic MCI: Cognitive
AD brain memory problems; decline
ch an ges start other cognitive a c ce lera tes
d e ca d es  before functions OK; after AD
symptom s brain co m p en sa tes diagnosis
show for ch a n g es
1 i
Normal age-related
memory loss
I  Total lo ss of
1 independent
i i i i |
1 functionVX
Birth 40 60 80 Death
Life Course
Healthy Aging Amnestic M CI m  Clinically Diagnosed AD
Fig. 1-3 The different phases of AD (NIH, 2008).
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The cause and pathways leading to AD are not yet completely clear. But three major 
competing hypotheses are currently discussed. The oldest is the cholinergic hypothesis, 
which proposes that AD is caused by reduced synthesis of the neurotransmitter 
acetylcholine. The other two are derived from the deposits found in the patient’s brain, first 
described by Dr. Alois Alzheimer, a German neurologist and psychiatrist in 1906 
(Alzheimer, 1907). He examined the brain tissue of a 51 year old woman, Auguste D., and 
found tangled bundle of fibrils within neurons (neurofibrillary tangles) (Honson and Kuret,
2008) and numerous patches of sticky proteins (|3-amyloid (AP)) (Hardy and Selkoe, 2002) 
in the space between neurons (Fig. 1-4). Both are hallmarks of AD.
Fig. 1-4: The hallmarks of AD A: plaques B: Neurofibrilar tangles http://edoc.hu-
berlin.de/dissertationen/becker-matthias-2006-07-17/HTML/image005.ipg.
Neurofibrillary tangles are mainly composed of the tau protein. In a healthy brain tau 
stabilises micro tubules. For this tau usually contains a certain number of phosphate 
molecules. In AD the protein gets “hyperphosphorylated” and detaches from the 
microtubules to form paired helical filaments which enmeshed with each other to form the 
tangles. As a result the microtubules disintegrate and the neuronal internal transport 
network collapses with a tremendous impact on the communication abilities of neurons. 
This abnormal aggregation of the tau protein and the lack of correlation between the 
amount of amyloid plaques and neuronal loss in some cases, suggested the formulation of
“Tau-hypothesis”, which is based on the assumption that tau is the major culprit of the
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disease (Honson and Kuret, 2008). Nevertheless, genetic, pathological and biochemical 
clues suggest that the progressive production and subsequent accumulation of p-amyloid 
(Ap), a proteolytic fragment (Api-40 or Api-42) of the membrane-associated amyloid 
precursor protein (APP), play a central role which led to the “Amyloid hypothesis” (Hardy 
and Selkoe, 2002). Support for this hypothesis comes from the location of the gene for the 
amyloid beta precursor protein (APP) on chromosome 21, and the fact that patients with 
trisomy 21 (Down Syndrome) who have an extra gene copy or the duplication of the APP 
locus (Rovelet-Lecrux et al., 2006) almost universally develop AD and that most of the 
familiar AD mutations are located inside the Ap sequence (Miyoshi, 2009). Furthermore 
most of the early onset AD cases are related to mutation of the AD gene and also APOE4, 
the major genetic risk factor for AD, leads to excess amyloid build-up in the brain before 
AD symptoms arise (Kim et al., 2009). Thus in these cases, Ap deposition precedes clinical 
AD.
AD is characterised by loss of neurons and synapses in the cerebral cortex and certain 
subcortical regions (NIH, 2008). It begins in the entorhinal cortex part of the temporal 
lobe, where healthy neurons begin to work less efficiently, lose their ability to 
communicate and finally die. Then, the hippocampus is afflicted and the ventricles increase 
their size. After the diagnosis of AD more and more parts of the cerebral cortex are 
affected and the number of plaques and tangles grows and the shrinkage of the concerned 
brain areas progresses further. Finally, when severe AD pathology is developed, the 
deposits of protein aggregates are widespread throughout the brain and further enlargement 
of the ventricles and an overall shrinkage of the brain is observed (Fig. 1-5).
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Fig. 1-5 Changes in the brain due to AD A: healthy brain B: Severe AD (N1H, 2008).
1.2.1 From APP to p-amyloid plaques in-vivo
After the isolation and determination of the Ap fragment as a main constituent of the 
extracellular plaques in 1984 (Glenner and Wong, 1984), it was found that these fragments 
are part of a much longer protein encoded on Chromosome 21 called the Amyloid 
precursor protein (APP) (Goldgaber et al., 1987).
APP is a transmembrane glycoprotein expressed in many tissues and concentrated in the 
synapses of neurons. Its primary function is not known, though it has been implicated as a 
regulator of synapse formation (Priller et al., 2006) and neural plasticity (Turner et al., 
2003). APP contains several distinct, largely independently-folding structural domains 
which reside on the extracellular region or intracellular region. APP undergoes extensive 
post-translational modification including glycosylation, phosphorylation, and tyrosine 
sulfation, as well as many types of proteolytic processing to generate peptide fragments 
(De Strooper and Annaert, 2000). There are two predicted cleavages necessary to release 
Ap from the precursor molecule. First the p-secretase cleaves the protein in the 
extracellular domain predominantly localised in the Golgi/TGN and endosomes, followed 
by the y-secretase mediated processing in the transmembrane region and subsequent 
release of Ap fragments (mainly A pl-40 and Apl-42) (see Fig. 1-6) during the 
endocytic/recycling step (Koo and Squazzo, 1994; Thinakaran and Koo, 2008). Available
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data indicate the presence of a y-secretase/Presenilin (PS) complex and enzyme activity in 
multiple compartments, including the ER, ER-Golgi intermediate compartment, Golgi, 
TGN, endosomes, and plasma membrane. Studies in non-neuronal and neuroblastoma cell 
lines suggest that Ap is generated mainly in the TGN. Nevertheless, y-secretase also exists 
as an intact complex on the plasma membrane which could form the Ap fragments and 
release them in the extracellular space (Chyung et al., 2005). These fragments are endowed 
with a high propensity to aggregate, so that if they are produced in excess and/or if they are 
not properly degraded, they tend to progressively form oligomeric, multimeric and fibrillar 
structures (plaques) involved in the neurodegeneration. Soluble oligomers may be 
responsible for cognitive dysfunction in the early stages of the disease.
The size and distribution of the toxic oligomer may vary during the disease progression 
and can be as small as a dimer (Shankar et al., 2008) or as big as a dodecamer (Lesne et al., 
2006). However, the aggregation and accumulation of Ap culminates with the formation of 
extracellular plaques, which may be surrounded by oligomeric species co-localizing with 
the postsynaptic density where they exert their toxic effects (Koffie et al., 2009). 
Nevertheless, plaques formation could also be a strategy of the organism to neutralise their 
toxic effect.
10
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Beta-secretase
Gamma-secretase
Fig. 1-6: From APP to beta-amyloid plaque in-vivo
The APP protein bound to a membrane is cleaved by y- and p- secretase and the aggregation prone 
Ap fragments are released into the extracellular space. Under this environmental condition the 
monomer can form oligomers which are thought to proceed to high ordered amyloid fibrils by 
monomer addition. Then the fibrils are deposited into plaques. (NIH, 2008).
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1.2.2 Molecular and cellular processes of AD pathogenesis: What goes wrong?
The current model for AD pathogenesis (Fig. 1-7), based on the amyloid hypothesis, is that
once Ap levels reach a threshold in the brain interstitial fluid, a pathogenic cascade is 
initiated. Aggregation and accumulation of Ap in the brain may result from increased 
neuronal production of Ap (Citron et al., 1994), decreased activity of Ap-degrading 
enzymes (Eckman and Eckman, 2005), or alterations in transport processes that shuttle Ap 
across the blood-brain barrier (Bates et al., 2009). Ap oligomers impair synaptic functions 
(Arendt, 2009; Shankar et al., 2008), whereas fibrillar amyloid plaques displace and distort 
neuronal processes (Grutzendler et al., 2007). Ap oligomers interact with cell-surface 
membranes (Valincius et al., 2008) and receptors (Verdier et al., 2004), altering signal- 
transduction cascades (Fuentealba et al., 2004), changing neuronal activities (Salehi and 
Swaab, 1999) and triggering the release of neurotoxic mediators by microglia (Gonzalez- 
Scarano and Baltuch, 1999). Vascular abnormalities impair the supply of nutrients and 
removal of metabolic by-products, cause microinfarcts and promote the activation of 
astrocytes and microglia (Shi et al., 2000; Zhu et al., 2007). The lipid-carrier protein 
apoE4, a risk-factor in AD, increases Ap production and impairs Ap clearance (Kim et al.,
2009). When produced within stressed neurons, apoE4 is cleaved into neurotoxic 
fragments that destabilise the cytoskeleton (Mahley and Huang, 2006) and, like 
intracellular Ap (Reddy, 2009), impair mitochondrial functions (Nakamura et al., 2009). 
AD related proteins like tau and a-synuclein (Gallardo et al., 2008) can also self-assemble 
into pathogenic oligomers and can form larger intra-neuronal aggregates, displacing vital 
intracellular organelles (Crews et al., 2009; De Felice et al., 2008; Fink, 2006; Gendron 
and Petrucelli, 2009; Qin et al., 2007).
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Fig. 1-7: Key players in the pathogenesis of AD (Mucke, 2009).
1.2.3 Kinetics of fibril formation in-vitro
It is thought that Ap fibril formation follows a nucleation-dependent polymerization 
reaction. But the investigation of this process revealed a complexity in numbers and types 
of assemblies and pathways which can lead to on- and off-pathway aggregates depending 
on the condition of the polymerization reaction (Fig. 1-8).
Protofibnl
‘ Natively unit ruttuted" P artially  struawed I7 f7 \
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Fig. 1-8: Kinetics of Fibril formation of Apl-42 (Roychaudhuri et al., 2009).
Ap is an amphipathic peptide. The N-terminus is mainly polar, since 12 of the first 28
residues are charged at neutral pH. The remaining 12 (Api-40) or 14 (Apl-42) side chains
are apolar which allows the formation of micelles (Lomakin et al., 1996) or direct
interactions with membranes. The turn forming residues A21-A30 are suggested to
13
Introduction
nucleate monomer folding because of their solvent inaccessibility. This region is resistant 
to proteolysis and maintain this in the isolated decapeptide as well (Krone et al., 2008). 
That turn can be destabilised by amino acid substitutions that cause familiar AD, which 
correlates with accelerated Ap oligomerization and higher-order assembly. In-vitro studies 
showed that Api-40 and Api-42 monomers adopted a predominantly a-helical structure in 
a membrane-mimicking environment (Coles et al., 1998) while a collapsed statistical coil 
is prevalent in aqueous solution (Bieschke et al., 2008; Danielsson et al., 2005; Gursky and 
Aleshkov, 2000; Klement et al., 2007) The monomer contains five relatively independent 
folding units, which are connected by four turn structures (Yang and Teplow, 2008). 
Molecular dynamics suggests that several monomeric conformers exist under physiological 
condition which are divided into two basins, comprising conformers with either substantial 
alpha-helix or beta-sheet (Yang and Teplow, 2008). Furthermore the addition of two 
hydrophobic amino acids 141 and A42 in Api-42 shifts the conformational equilibrium 
towards beta-sheet structure. This is mediated by the increase of contacts within the C- 
terminus and the additional interaction between the C-terminus and the central 
hydrophobic cluster (CHC) (L17-A21) (Yang and Teplow, 2008), and could explain the 
higher aggregation propensity of Apl-42 and possibly explains the higher toxicity 
(Dahlgren et al., 2002). On the contrary, the N-terminus might be more important in 
stabilizing the monomer of Api-40, thereby hindering the oligomerization. It was shown 
by NMR (Lim, 2006) and molecular dynamics (Yun et al., 2007) that the N-terminus of 
Api-40 is more partially stabilised and more structured with a possible formation of beta- 
sheet structure spanning residue A2-F4. Furthermore, in Api-40 this region is suggested to 
stay in contact with the CHC and could inhibit intermolecular interactions of the critical 
residues (histidines and L17VFFA21) (Lim, 2006).
The importance of the C/N-terminus of Apl-40 and Api-42 in controlling the 
oligomerization has been revealed by experiments involving AD related amino acid
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substitutions in the C-terminus and truncation of sequences in the N-terminus (Bitan and 
Teplow, 2004). The authors used photoinduced Cross-Linking of Unmodified Proteins 
(PICUP) to stabilise the metastable oligomers (Bitan et al., 2003a) which allowed the study 
of Ap oligomerization pattern. The oligomerization patterns of the unmodified Api-40 
showed that the fragment exists as monomer, dimer, trimer, and tetramer and Api-42 as 
pentamer, and the important hexamer units, termed paranuclei. Bernstein et al. confirmed 
these results and additionally suggested the formation of Apl-42 dodecamer as primary 
toxic species (Bernstein et al., 2009). All these metastable smaller oligomers are formed 
rapidly, and in equilibrium with the monomer. Native gel electrophoresis of un-crosslinked 
peptides revealed that Apl-40 forms unstable monomers, whereas Api-42 forms stable 
trimers and tetramers prior to fibril formation (Chen and Glabe, 2006). Modification at 
position 22 (E22Q, E22G, E22K and D23N) led to higher order Api-40 oligomers, but had 
little effect on the oligomerization patterns of Api-42 (Bitan and Teplow, 2004). 
Furthermore, the removal of N-terminal residues N1-G9 in Apl-42 had no effect on its 
oligomer size distribution, whereas truncation of up to four N-terminal residues of Api-40 
produced higher-order oligomers. Interesting is also the fact that an antibody directed 
against residues 4-10 of Api-42, inhibits both Ap fibrillogenesis and 
cytotoxicity.(McLaurin et al., 2002).
The structure determination of these early oligomers is a difficult task. Recently Ono et al. 
reported a study in which specific Api-40 oligomers have been stabilised structurally, 
fractionated in pure form, and then studied by using a combination of CD spectroscopy, 
Thioflavine T fluorescence, EM, atomic force microscopy (AFM), and neurotoxicity 
assays (Ono et al., 2009). These spherical oligomers (up to tetramer) exhibited order- 
dependent increases in p-sheet content, toxicity and fibril nucleation activity. This suggests 
that these assemblies are on the pathway of fibril formation, which is preceded by 
protofibril formation (Caughey and Lansbury, 2003). These study and the work of Chimon
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et al. (Chimon et al., 2007) revealed a large conformational change between the 
unstructured monomer and the spherical oligomers while the transition from the oligomer 
to protofibrils and fibrils involves tighter packing of p-sheet.
Protofibrils in AD, were described as beaded chains, short, unbranched, p-sheet rich, and 
rod-like structure. Oligomers and protofibrils exist in equilibrium with each other. For 
Apl-42 pentamer or hexamer, the “paranucleus,” was suggested to be the basic unit of the 
protofibril and that the beaded chains comprising protofibrils formed by the self­
association of paranuclei (Roychaudhuri et al., 2009). Furthermore, structural differences 
between protofibrils and mature amyloid fibrils were determined by hydrogen-deuterium 
exchange-mass spectrometry (HX-MS) coupled with on-line proteolysis for Api-40 
(Kheterpal et al., 2006; Williams et al., 2005). It was shown that 12 of the backbone amino 
acids were protected from exchange in protofibrils and 22 in fibrils. The C-terminal 
segment 35-40 and the N-terminal segment 1-19 are highly exposed in both fibrils and 
protofibrils and the internal fragment 20-34 is highly protected in fibrils but much less in 
protofibrils. Interesting is the fact that the Thioflavine T and Congo-red sensitive p-sheet 
elements are already present in protofibrils, which are expanded into some adjacent 
residues upon the formation of mature amyloid. This suggests that protofibrils are on 
pathway of fibril formation and that the transition from protofibril to fibril involves 
substantial ordering of Ap peptide inside the assembly.
This structural flexibility explains the polymorphism (Fandrich et al., 2009; Kodali and
Wetzel, 2007; Wetzel et al., 2007) of fibril structures observed in electron microscope and
atomic force microscope (Goldsbury et al., 2000). The reorganization and its resulting
fibril structure depend on the precise details of growth. Petkova et al. have shown that
fibrils formed under quiescent condition, differ in morphology and also have significantly
different toxicities in neuronal cell cultures compared to non-quiescent condition (Petkova
et al., 2005). Interestingly, the different structural motifs are conserved upon seeding
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independent from the condition and are different in their toxic effect on neuronal cells. 
This finding prompted Paravastu et al. to investigate the structure of Api-40 fibrils 
produced by seeded growing from fibrils extracted from brain tissue of deceased AD 
patients (Paravastu et al., 2009). They found that this fibrils formed from brain aggregates 
are different to the fibrils formed in-vitro. The determination of the fibril structure has been 
an unusually difficult task because Ap preferentially form amyloid fibrils rather than 
protein crystals. Solid-state NMR studies have revealed that Ap fibrils could comprise p- 
strands organised in a parallel, in-register fashion (Nelson and Eisenberg, 2006) or form 
parallel p-sheets between residue 12-24 and 30^10 connected by a turn involving residues 
25-29 (Tycko, 2006). This is also determined to be the most likely structure when 
experimental X-ray diffraction patterns were compared to calculated diffraction patterns 
(Jahn et al., 2009). Recently the supramolecular structure of Api-42 fibrils were probed by 
cryo-EM and real-space reconstruction method (Zhang et al., 2009). The findings suggests 
that 2 protofilaments wind around a hollow core and that, to the contrary of Api-40 fibril 
models, the C-terminus forms the inside wall of the hollow core, which was supported by 
partial proteolysis analysis. Nevertheless the turn is still present in the monomer. In 
another model it was suggested that cross-P sheet pairing between two extended monomers 
which resembled the recently proposed steric zipper model (Sawaya et al., 2007) form the 
core of the fibril (Schmidt et al., 2009)
1.2.4 Other Ap oligomers
The importance of the Ap hexamer as a building block comes from the observation that at 
least four diverse assemblies, Ap derived diffusible ligands ADDLs (Lambert et al., 1998), 
A*56 (Lesne et al., 2006),“globulomers,” (Barghom et al., 2005b) and “ApO” (Kayed et 
al., 2003) comprise multiples of this basic unit.
Even though, some controversy about the size of ADDLs exists in literature, it is now 
becoming clear that they are composed of two hexameric units (dodecamer) (Chromy et
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al., 2003; Hepler et al., 2006). ADDLs were found to kill mature neurons in hippocampal 
slice cultures and are produced in vitro from Api-42 under special solvent conditions 
(Lambert et al., 1998; Stine et al., 2003).
The 56 kDa “A*56” oligomer which is consistent with a dodecamer, was identified in SDS 
extracts from brains of Tg2576 transgenic mice.
A third type of dodecamer is the globulomer (a globular oligomer). This Api-42 derived 
oligomer is formed in the presence of SDS close to the critical micelle formation 
concentration of SDS (Barghom et al., 2005b). Protease digestion, antibody binding, mass 
spectrometry and NMR studies of globulomers (Yu et al., 2009) soluble forms have a 
mixed parallel and antiparallel P-sheet which are different to the structure of the monomer 
inside the fibril. Although the secondary structure of globulomers is mainly P-sheet, they 
are not ThT sensitive and do not form fibrils (Gellermann et al., 2008; Rangachari et al., 
2007). This suggests that this oligomer is an off-pathway assembly. A 90 kDa larger 
species, the A oligomer, also has been produced in vitro. That assembly is consistent with 
that of an octadecamer.
1.2.5 Mutations in AD and early onset of the disease
Early-onset Alzheimer’s disease is the term used for cases of AD diagnosed before the age 
of 65 (Miyoshi, 2009). It is uncommon and accounts for only 5-10% of the cases. 
Approximately half of them are Familial Alzheimer’s disease (FAD), where a genetic 
mutation, mainly inherited in an autosomal dominant fashion, leads to the disease.
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Fig. 1-9: The cleavage sites and loci of mutation of the Ap sequence. (Thinakaran and Koo, 2008)
The blue dots indicate the amino acid were mutational variants were discovered.
Besides missense mutations in presenilins 1 and 2 gene, alteration of the APP gene has
been linked to FAD (Fig. 1-9) (Goate et al., 1991; Levy-Lahad et al., 1995; Sherrington et
al., 1995). Mutations in APP generally increase the ratio of the Aj31-42/Apl-40, the
amount of fragments produced (e.g. Swedish APP double mutation increases the overall
production of Ap by enhancing p-secretase cleavage) or increases the aggregation
propensity of one o f the fragments. Most intra- Ap amino acid substitutions affect peptide
self-association. For example, the Arctic mutation that causes an E22G substitution and
early-onset FAD enhances the formation of protofibrils (Nilsberth et al., 2001) and fibrils
of Ap in vitro (Murakami et al., 2002) and the deposition of Ap in vivo in the brains of
transgenic mice (Cheng et al., 2004; Lord et al., 2006). The Dutch (E22Q), Italian (E22K),
or Iowa (D23N) mutations have been shown to enhance the formation of protofibrils or
fibrils from Ap in vitro (Miravalle et al., 2000; Van Nostrand et al., 2001; Walsh et al.,
1997) and produce parenchymal or vascular Ap deposits in the brains of transgenic mice
(Davis et al., 2004; Herzig et al., 2004). Taken together, the intra-Ap mutations at position
22, 23 appear to enhance the deposition of Ap by increasing the propensity of Ap to
aggregate whereas the terminal mutation enhance cleavage of Ap fragments or change the
ratio between Apl-40/Api-42. A combination of these two properties is seen in recently
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discovered recessive mutation in the N-terminus of Ap (A2V) where the production of the 
Ap fragments is increased and also the kinetics of fibril formation is accelerated (Di Fede 
et al., 2009). On the contrary, fibril formation was omitted and the formation of oligomers 
enhanced by the deletion of amino acid G22. These Ap oligomers accumulate intracellular, 
cause endoplasmic reticulum stress-induced apoptosis in cultured cells (Nishitsuji et al., 
2009) and are rich in p-sheet structure (Wang et al., 2009).
1.2.6 Surface-induced formation of Ap assemblies
Surface properties such as hydrophilicity can influence the aggregation of Ap (Kowalewski 
and Holtzman, 1999). Kowalewski et al. found that oligomeric Apl-42 formed mobile, 
nanoscale pseudomicellar aggregates on mica, and uniform, elongated sheets oriented 
along the crystallographic axis reminiscent of protofibrillar species of the graphite surface. 
This suggests that both hydrophilic and hydrophobic surface interactions at the cell 
membrane may influence aggregation and toxicity.
Besides interaction of Ap with phospholipids (McLaurin and Chakrabartty, 1997), 
gangliosides (McLaurin et al., 1998) and cholesterol (Yip et al., 2001), membrane 
mimicking compounds like SDS have shown the influence on the assembly formation and 
toxicity Ap aggregates (Barghom et al., 2005b; Rangachari et al., 2007; Rangachari et al., 
2006; Tew et al., 2008)
1.2.7 Metals in AD
Neurodegenerative diseases are associated to misbehaviour of the metabolism of metal
ions. Although several biological transition metals can precipitate Ap (Bamham and Bush,
2008; Ha et al., 2007), only copper and zinc, which are released during glutamatergic
activity, have been found to directly bind Ap in plaques (Dong et al., 2003; Opazo et al.,
2002), which contain highly enriched concentrations of zinc, copper (Stoltenberg et al.,
2005) and iron as ferritin complex (Quintana et al., 2006). There is clear evidence that
metal ions mediate the oxidative stress mechanism of Ap and form Reactive Oxygen
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Species (ROS) such as hydrogen peroxide (H2O2) (Allsop et al., 2008). As a result marked 
oxidative injuries occur, that include protein DNA and RNA oxidations and lipid 
peroxidation (Butterfield et al., 2007).
2"hAp has a strong positive reduction potential and displays high-affinity binding for Cu , 
Zn2+, and Fe3+ ions (Kawahara et al., 1997). Solution-state NMR and EPR have suggested 
that the three His residues in Ap, (His6, Hisl3, and His 14), coordinate Cu2+. The Ap
9-1- 14-coordination of Cu and reduction of Cu to Cu leads to the generation of ROS. For 
instance, H2O2 is generated in the early phase of aggregation during protofibril or oligomer 
formation which later is converted to a reactive hydroxyl radical via Fenton chemistry 
(Allsop et al., 2008), which is accompanied by the oxidation of another moiety, such as 
cholesterol (Puglielli et al., 2005) or Ap side-chains (Hureau and Faller, 2009). 
Electrospray ionization mass spectrometric analysis indicated the formation of methionine 
sulphoxide, methionine sulphone and related hydroxylated products which suggests that 
methionine 35 (Met35) could be a second centre of redox chemistry (Ali et al., 2005; 
Butterfield, 2003). Oxidation of Met35 in Apl-42 blocked paranucleus formation and 
produced oligomers indistinguishable in size and morphology from those produced by 
Api-40 (Bitan et al., 2003b) and significantly reduced the rate of amyloid formation and 
alters fibril morphology (Hou et al., 2004).
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1.3 Chemical synthesis of proteins
Solid phase peptide synthesis (SPPS) was first proposed by R.B. Merrifield in 1963 
(Merrifield, 1963). Even though many proteins can be prepared by recombinant peptide 
synthesis, the chemical synthesis is a valuable tool. In particular, the formation of cytotoxic 
sequences or the incorporation of non-natural amino acids or other chemical building 
blocks is not possible without this technique. At present small proteins containing up to 60 
amino acids can easily be prepared by linear SPPS. Longer peptides are prepared by the 
synthesis of small peptide fragments of the whole sequence and are later fused by fragment 
condensation (Chan et al., 2000). The principle of SPPS is shown in Fig. 1-10. For this a 
C-terminal unprotected amino acid is coupled to a linker who resides on a resin. Side 
chains and the Na-amino function are protected by various groups. After the coupling the 
Na-amino protecting group is removed and the next amino acid is attached to the sequence 
by peptide bond formation. The coupling is done eihter by ex-situ pre-activated Na- 
protected amino (symmetric anhydride) or in-situ by activation of the C-terminus with 
guanidinium type coupling reagents (Marder and Albericio, 2004). In this way the whole 
sequence from the C- to the N-terminus is built in a stepwise manner, which will be 
cleaved from the resin in the end of the synthesis. Essentially two synthesis strategies are 
available. One is the by Merrifield proposed acid labile Boc/Bzl method and the other the 
base labile Fmoc/tBu, which uses orthogonal protection strategy. Furthermore, this 
procedure operates under milder conditions.
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Fig. 1-10: Solid phase peptide synthesis (Amblard et al., 2006).
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“Difficult sequence” has long frustrated chemists in their efforts to assemble peptides that 
contain such sequences by solid phase synthesis methods. Peptides containing p-sheet 
structures are thought to belong to this type of sequence. Possibly, these peptides are prone 
to form inter- or intra molecular interaction during the stepwise synthesis even in the 
presence of organic solvents. It is likely the formation of hydrogen bonds and the 
interaction between of hydrophobic side chain protection groups which are responsible for 
the poor salvation. As a result shrinkage of the resin, low reagent accessibility and the 
steric hindrance on the amino-terminus are observed. This could lead to incomplete 
acylation or cleavage of the Na-protection group, which produces deletion or truncation 
sequences. This lowers the yield of the product or even makes the purification impossible. 
In the last 30 years progress has been made to overcome these problems.
Variation of the reaction condition made a lot of difficult sequences available to chemical 
synthesis. It was shown that changes in solvent composition, the use of chaotropic salts, 
variation of resin loading, more efficient reaction compounds (e.g. coupling and de­
protection reagents) and elevated temperatures improve significantly the synthesis of 
difficult sequences (Tickler et al., 2004).
Problems are observed in the Fmoc chemistry as well as in the Merrifield methods. For 
instance, aggregation induced products formation which is reduced by in-situ neutralisation 
of the remaining Trifluoroacetic acid (TFA) after Boc-deprotection. This was later 
successfully translated to the Fmoc synthesis by washing the resin with an acidic solution 
just before the coupling step. This significant improvement could be due to the breakage of 
the amide hydrogen bonds. Nevertheless there is the risk that parts of the peptide and/or 
side chain protection groups are cleaved under this condition, which in turn reduces the 
purity and yield of the synthesis.
The observation that peptides containing Na-alkyl-amino acids and Proline are often
synthesised without difficulties led to the development of reversibly Na-alkylated amino
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acids (Coin et al., 2007). Amide-protected building blocks, such as those shown in Fig. 
1-11, can be used to improve the efficiency of Fmoc solid phase peptide synthesis of 
aggregation-prone sequences. Many of these building blocks are commercially available 
and are easily incorporated into the sequence during the automated peptide synthesis.
O-Acyl Isopeptide (depsi)Pseudo-Proline-DipeptideFmoc-(FmocHmb)-AA-OH
COOH
Fmoc'.OHFmoc.
Fmoc' HN
Boc
‘O—FmocMeO'
Fig. 1-11: Amide backbone modification strategies for the synthesis of difficult sequences.
These Na-alkylated amino acids are incorporated into the sequence instead of the non 
alkylated amino acids and reconverted into the native residue. For instance the 2-Hydroxy- 
4-methoxybenzyl (Hmb-) group disturbs the structure formation for the following six 
amino acids, improves in this way the salvation of the sequence and is removed from the 
sequence during the final TFA cleavage step.
Pseudoprolines developed by Manfred Mutters laboratory (Wohr, 1995) are temporary 
cyclic protection building blocks for SPPS (Ser/Thr-derived oxazolidines or Cys-derived 
thiazolidines).They have similar to Proline the capability to disrupt secondary structure due 
to their restricted dihedral angles.
Another tool is depsipeptides. This new synthesis technique (the so called Depsipeptide- 
technique) requires, like the pseudoprolines, Ser/Thr/Cys to be present in the sequence. 
This technique has already been applied to Api-42 (Sohma et al., 2007). As regards to the 
latter, in particular, the synthesis includes the formation of an ester bond between the side 
chain hydroxyl group of serine26 and the next incoming amino acid. Extreme care has to 
be taken in choosing the right experimental condition, since the presence of a strong base 
and the use of polar solvents lead to beta-elimination (formation of deletion sequences) and
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chiral impurities of the final product. The native sequence of peptide is regained by an O-N 
intramolecular acyl migration step under neutral condition. Additionally to the capability to 
avoid the formation of secondary structures during the synthesis, it extremely improved the 
solubility of the peptide after the final cleavage step, since the depsipeptide remains stable 
as a TFA salt or under acidic condition. The resulting Depsi-Api-42 is much more 
hydrophilic, with a 100-fold greater water solubility (15 mg/ml) compared to the native 
Apl-42 prepared by standard synthesis protocols (0.15 mg/ml) (Sohma et al., 2004b).
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1.4 Disaggregation and peptide preparation
Many peptide preparations of Api-40 can be contaminated with pre-existing aggregates 
(seeds) capable of acting as cytotoxic agents (Howlett et al., 1995), to accelerate the 
aggregation of the monomeric peptides (Evans et al., 1995), or as inhibitors of spontaneous 
aggregation (Wood et al., 1996). Numerous disaggregation methods have been described, 
which include filtration of dimethyl sulphoxide (DMSO) solutions (Evans et al., 1995), 
sequential, treatment with TFA and/or hexafluoroisopropanol (HFIP) (Bartolini et al., 
2007; ONuallain et al., 2006; Wood et al., 1996; Zagorski et al., 1999), ultracentrifugation 
of aqueous solutions (Zhang et al., 2000), dissolution in basic aqueous solution followed 
by filtration or size exclusion chromatography (SEC) (Teplow, 2006). Disaggregation is a 
must, even if the experiment doesn’t aim to investigate details of assembly kinetics and 
mechanism. This is due to the polymorphism in the fibril structure depending on the 
condition during preparation (Petkova et al., 2005; Tanaka et al., 2004).
Each method has potential advantages and disadvantages. One problem arises during the 
dissolution step of the peptide powder or peptide film in aqueous sodium hydroxide 
(NaOH) solution, since intense vortexing induces precipitation (O'Nuallain et al., 2006; 
Teplow, 2006). Bartolini et al. added acetonitrile (AcN) to the basic solution to circumvent 
this problem (Bartolini et al., 2007). They demonstrated that CD experiments designed to 
investigate the transition from random state to P-sheet were highly reproducible. 
Nevertheless, the velocity of the transition depended on the AcN concentration.
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1.5 Aggregation inhibitors: A strategy in AD treatment
The available medications to treat AD fall into two classes, acetylcholinesterase inhibitors
(donepezil, galantamine, rivastigmine, and tacrine) and N-methyl-d-aspartate (NMDA) 
antagonists (memantine). These drugs ameliorate the symptoms, but do not halt or reverse 
the illness. Many studies have postulated that the aggregation of Ap in both soluble and 
insoluble forms in the brain is likely a key initiating factor in AD pathogenesis. Thus, 
controlling the aggregation process is a potential target. Great effort is undertaken to 
develop treatments which interfere with Ap plaques and tau-based neurofibrillary tangles 
(Neugroschl and Sano, 2009). Amyloid-based therapies include y-secretase inhibitors and 
modulators, BACE inhibitors, aggregation blockers, catabolism inducers, and anti-AP 
biologies (Fig. 1-12) (Barten and Albright, 2008).
Degraded
Ap42
Oligomers
APP protein Amyloid Plaques
BACE
Cognitive deficits
Y - s e c r e t a s e
Fig. 1-12: Therapeutic strategies based on the “amyloid hypothesis”
A number of therapeutic strategies is currently being examined, both in the laboratory and in the 
clinic, which aim to reduce the amyloid load in the brain. These strategies can be broadly 
categorized as: (1) preventing or reducing the production of Ap (pharmacological inhibitors of the 
enzymes responsible for APP metabolism), (2) direct or indirect targeting Ap neurotoxicity, (3) 
preventing Ap oligomerization and deposition, (4) enhancing Ap degradation and (5) improving Ap 
clearance from the brain across the blood-brain barrier (BBB) and into blood plasma.
There are numerous phases I and II clinical trials underway for a wide variety of new 
therapeutic approaches for the treatment of AD. Phase III clinical trials are in progress for 
y-secretase inhibitors, an Ap modulator, passive immunization of Ap, and an Ap 
aggregation inhibitor (Neugroschl and Sano, 2009).
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Ap aggregation inhibitor should stabilise a specific alloform (possibly the a-helical form) 
of the mainly disordered state of the monomer, resulting in complete blockage of 
oligomerization and fibril formation. Nerelius et al. showed for instance that compounds 
designed to interact with and stabilise the Ap 13-23 helix alter the aggregation properties of 
AP in vitro and reduce Ap toxicity toward PC 12 cells and hippocampal slice preparations 
(Nerelius et al., 2009). A second approach would be the stabilization of the less extended 
form of the Ap monomer within the oligomer or in incoming monomers. But one 
requirement is that this strategy must not stabilise toxic oligomers, unless inhibitor binding 
blocks toxicity. Third, a complete destabilization of oligomers which are rich in p-sheet 
structure and higher in toxicity compared to monomer and fibrils could be a valuable 
strategy for inhibition of aggregation (Chimon et al., 2007; Roychaudhuri et al., 2009; Yu 
et al., 2009). And finally the dissociation of fibril could be used to decrease the amyloid 
burden in-vivo, but only if the formed assemblies are not toxic.
1.5.1 P-sheet binding compounds
Dyes like Congo red, chrysamine G, and Thioflavine S/T bind the cross-P-structure 
common to all amyloids (Fraser et al., 1992). Congo red attenuates fibrillogenesis, inhibits 
Ap-induced toxicity, and reduces oligomeric Ap production (Lorenzo and Yankner, 1994; 
Podlisny et al., 1995). Congo red possibly binds to the exposed N-terminal histidine 
residues (Hisl3, His 14) and influences in this way the fibrillogenesis (Inouye and 
Kirschner, 2000).
1.5.2 p-sheet breaker peptides
The determination of key residues important for aggregation led to the design of 
pentapeptide homologous of Ap based on the hydrophobic residues of the CHC which 
inhibited fibril formation, by binding to Ap40 to stabilise P-sheet structure (Esteras-Chopo 
et al., 2008; Tjemberg et al., 1997; Tjemberg et al., 1996). However, this so called “plaque 
busters” (Soto, 1999) are capable of self-associating into fibrils.
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The potential for Proline residues to hinder p-sheet formation (Morimoto et al., 2004; 
Williams et al., 2004) led to the design of modified fragments of the CHC (LVFF to 
LVPP). This resulted in peptides which inhibit fibrillogenesis and disaggregate preformed 
fibrils in vitro (Soto et al., 1996)
Other inhibitors including the CHC recognition element, and additionally contained a 
disrupting element were probed. The inhibitor KLVFF-KKKKKK altered Ap aggregation 
by altering aggregate morphology and kinetics, while protecting against Ap-induced 
toxicity (Pallitto et al., 1999)
Because of the importance of hydrogen bonding in stabilizing P-sheet formation (Luhrs et 
al., 2005), the methylation of backbone amide nitrogen disrupted interstrand hydrogen 
bond formation and attenuated fibrillogenesis (Sciarretta et al., 2006). Alternatively, 
replacement of amide bonds with ester bonds also results in a monomeric, soluble peptide, 
which is capable of inhibiting aggregation and disaggregating preformed fibrils (Gordon et 
al., 2002). However, peptide inhibitors are not currently being pursued in clinical trials
1.5.3 Modulation of structural transitions
Several small molecules that inhibit the in vitro formation of amyloid fibrils from
monomeric Ap have been identified (Findeis, 2000; Hamaguchi et al., 2006; LeVine, 2007)
Studies using quantitative measures of inhibition assembled from light scattering
measurements, ThT fluorescence, or immunoassays have facilitated comparisons of
inhibitory potential among different molecular structures (Dolphin et al., 2008; Ferrao-
Gonzales et al., 2005; Howlett et al., 1999a; Howlett et al., 1999b; Ono et al., 2003; Reinke
and Gestwicki, 2007; Simons et al., 2009). Most of these studies, however, have quantified
the effect of small-molecule inhibitors on the overall extent of fibril formation without
considering the high complexity and multitude of possible on-/off-pathways Ap
assemblies, like oligomers, protofibrils, and other soluble aggregates (LeVine, 2007;
Necula et al., 2007b). Some small-molecule inhibitors selectively halt the formation of
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mature Ap fibrils from monomer without stopping the formation of soluble aggregates 
(Bohrmann et al., 2000) or the growth of preformed fibrils (LeVine, 2007). Alternatively, 
small-molecule inhibitors can promote fibril formation, inhibit ongoing fibril growth 
(Williams et al., 2005) or selectively inhibit different mechanisms of soluble aggregate 
growth (Moss et al., 2004). In addition, although some small molecules prevent both 
oligomer and fibril formation (De Felice et al., 2004; Howlett et al., 1999b; Necula et al., 
2007b; Yang et al., 2005), other inhibitors halt the appearance of oligomers without 
altering mature fibril formation (Necula et al., 2007a) or, conversely, block the appearance 
of mature fibrils while permitting oligomer formation (Ferrao-Gonzales et al., 2005; 
Lashuel et al., 2002; Necula et al., 2007b). These qualitative studies suggest that small- 
molecule inhibitors of Ap self-assembly can selectively act on various assembly pathways.
For example (-)-Epigallocatechin-3-gallate (EGCG) binds to natively unfolded Ap, 
reduces ThT fluorescence, and promotes the assembly of large, spherical oligomers. EGCG 
redirects the aggregation to a disordered off-folding pathway that results in the formation 
of non-toxic amorphous aggregates which are unable to seed fibrillogenesis (Ehmhoefer et 
al., 2008). Another compound is curcumin, the main constituent of the spice turmeric, 
whose extensive use is thought to account for the significantly lower prevalence of AD in 
the Asian Indian population (Ganguli et al., 2000). Curcumin inhibits fibril formation, 
extension, and destabilised preformed fibrils at nanomolar concentrations (Ono et al., 
2004b). Furthermore it inhibits Apl-42 oligomer formation and toxicity in-vitro, and binds 
to plaques and reduces amyloid levels in-vivo (Yang et al., 2005).
1.5.4 Current clinical trials using aggregation modulators
The most promising compound in development was ionic compound 3-amino-1- 
propanesulfonic acid 3-APS, (also known as tramiprosate, homotaurine, and Alzhemed 
[Neurochem, Laval, Canada]. 3-APS was found to maintain Ap in a non-fibrillar form, 
decreased Ap deposition in transgenic mice, and significantly decreased the cerebral levels
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of soluble and insoluble Ap (Gervais et al., 2007). However, the phase 3 trial in the United 
States was reported as inconclusive, and the phase 3 trial in Europe was halted before the 
data were released. Currently another agent, scyllo-inositol, is in phase 2. It appears to bind 
oligomers of Apl-42, preventing them from damaging synapses (McLaurin et al., 2000; 
Sun et al., 2008b).
1.5.5 Tetracyclines (TCs): small compounds for AD treatment?
TCs have been shown to interact with assemblies of various non-sequence related proteins
in peripheral and central amyloidosis in-vitro and in-vivo (reviewed by (Forloni et al., 
2009) e.g. PrPSc and related fragments (Tagliavini et al., 2000), Api-42 (Forloni et al., 
2001), transthyretin (Cardoso et al., 2003; Cardoso and Saraiva, 2006), W7FW14F 
apomyoglobin (Malmo et al., 2006), amylin (Aitken et al., 2003), huntingtin (Smith et al.,
2003) and a-synuclein (Ono and Yamada, 2006).
Various publications investigate the interaction of TCs with Ap derived fragments in-vitro. 
Howlett et al. claimed that only RTC suppresses Api-40 fibril formation effectively with 
an IC50 of 59 pM in a fibril-dependent immunoassay, whereas other compounds are less 
(OTC (34% of inhibition at 250 pM), TC (20% of inhibition at 250 pM)) or not effective at 
all (CTC, DMC, DC, MC) (Howlett et al., 1999b). Another study showed that TCs (TC 
and DC) not only inhibited the beta-amyloid aggregates formation but also disassembled 
the pre-formed fibrils of Apl-42 (Forloni et al., 2001). This capacity was determined by 
electron microscopy and quantified with ThT binding assay. The self-aggregation capacity 
was reduced by nearly 50% at a compound concentration of around 60 pM and 40% 
preformed fibrils were disassembled at 220 pM TCs concentration. Furthermore, the 
resistance of aggregates to trypsin digestion was reduced. The EC50 (effective 
concentration) for aggregation inhibition of TC determined via Thioflavine-T by Ono et al. 
was with 10 pM Api-40 and 10 pM Apl-42 (Ono et al., 2004a) lower. TC showed also a 
greater potential in destabilization of preformed fibrils (EC50; 23 pM Api-40 and 45 pM
Introduction
Api-42). Furthermore, the authors found that the extension of fibrils in a seeded reaction 
was suppressed. This suggests a direct interaction of TC with the p-amyloid structure. 
Support comes from the finding of Bartolini et al., where the slope of the exponential 
growth of p-sheet structures followed by CD was decreased in the presence of TC, but the 
lag phase did not change (Bartolini et al., 2007). An indirect method for the determination 
of binding potential of TCs was used by Inbar et al. (Inbar et al., 2008). They investigated 
the potential of molecules for their ability to associate with fibrils formed from synthetic 
Ap peptides by monitoring their ability to inhibit the interaction of a monoclonal anti-Ap 
IgG with these fibrils. OTC (IC50=144 pM), CTC (IC50=63 pM) and TC (IC50=8.2 pM) 
interfered with the binding of the antibody whereas DC and RTC didn’t have an effect. 
Another study reported the use of X-ray fibre diffraction in characterizing the inhibition of 
Ap fibrillogenesis (Kirschner et al., 2008). They investigated the effect of TC on the 
aggregation of Ap (11-25) and AP (12-28) on the integral widths and integrated intensities 
of the two characteristic reflections at 4.7 A and ~10 A. They found that the volume of the 
P-crystallites is reduced in Ap (12-28) and Ap (11-25) using 6.93 mM TC but the coherent 
domain sizes along inter-sheet and H-bonding direction is not significantly altered (see 
Fig4 bottom in (Kirschner et al., 2008)). On the contrary, plaque formation by Api-40 
added to primary human macrophages was not impaired by addition of TC (Gellermann et 
al., 2006).
Presently, several studies are focused on the therapeutic potential of TCs, mainly MC in 
AD. Accumulation evidence suggests the neuroprotective effects of MC on AD models 
affecting various pathways, which underlines the potential for being an effective and safe 
AD therapeutics (Kim and Suh, 2009). It has been shown that MC reduces microgliosis, 
the expression of inducible nitric oxide synthase, caspase-1 activity, formation of 
interleukin lb, metalloprotease activity, and production of cyclooxygenase and 
prostaglandins.
33
Introduction
Table 1-2 Effects of Minocycline in AD (adapted from (Kim and Sub, 2009)).
APP transgenic mice: suppress microglia production o f IL -ip , IL-6, TNF-a (Seabrook et al., 2006) 
attenuate the increases in peIF2-a in hippocampus (Choi et al., 2007) 
attenuate cognitive impairment (Choi et al., 2007)
Adult human 
microglia:
downregulates pro-inflammatory cytokines (Familian et al., 2006; Rogers et al., 
2002)
mu p75-saporin 
injected mice models
attenuates cholinergic cell loss, glial activation, transcription o f downstream pro- 
inflammatory mediators (Hunter et al., 2004)
Api-42
injected/infused rat 
models
inhibit neuronal cell death (Familian et al., 2007)
decrease microglia and astrocyte numbers, COX-2 expression and 3-nytrosine
(Familian et al., 2007; Ryu and McLamon, 2006)
attenuate the increases in peIF2-a in hippocampus (Choi et al., 2007)
Ap 25-35 infused rat 
models
protect against alterations o f somatostatin signalling pathways (Burgos-Ramos et 
a l, 2008)
MC reduced also nitric oxide (NO) levels by inhibition of p38 activation (Lin et al., 2001). 
NOs and its derivative (reactive nitrogen species), also belonging to the group of ROS, are 
known to inhibit the mitochondrial respiration (Brown and Borutaite, 2006) which is 
thought to play an important role of mitochondrial dysfunction in the pathogenesis of AD, 
since NO levels are increased in PC 12 cells and human embryonic kidney cells bearing the 
Swedish double mutation in the APP gene (Keil et al., 2004). Other TCs like TC have been 
found to decrease NO-levels as well (D'Agostino et al., 1998). In cultured rat cerebellar 
granule neurons treated with 6-hydroxydopamine, MC attenuated free-radical production 
and cell death (Lin et al., 2003), which could be realised by direct radical scavenging 
(Kraus et al., 2005). Nevertheless, the radical scavenging potential is greatest for MC and 
lowest for TC (MC>CTC>DC»TC) which supports the finding that other pathways are 
affected by the compounds (D'Agostino et al., 1998; Kim and Suh, 2009).
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1.6 Tetracycline
1.6.1 Nomenclature and structure
The Tetracyclines (TCs) are a group of structurally-related antibiotics and so named for 
their four (“tetra-”) hydrocarbon rings (“-cycl-”) derivation (“-ine”). They are a subclass of 
polyketides having an octahydrotetracene-2-carboxamide skeleton, substituted with many 
hydroxyl and other groups (Table 1-3).
Table 1-3. Chemical formula of various TCs.
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BCD-chromophore A-chromophore
Derivative abbreviation R l R2 R3 R4 occurrence
Tetracycline TC H OH CH3 H n.o
Oxytetracycline OT H OH CH3 OH n.o.
Chlorotetracycline CTC Cl OH CH3 H n.o.
Desmethylchlorotetracyline DMCTC Cl OH H H s.s.
Doxycycline DC H H CH3 OH s.s.
Rolitetracyline RTC H OH CH3 s.s.
Minocycline MC N(CH3)2 H H H s.s.
Benjamin Mingo Duggar in Lederle Laboratries in Pearl River (US) discovered the first 
TC from a golden-coloured, fimgus-like, soil-dwelling actinobacteria named Streptomyces 
aureofaciens in 1947 (Duggar, 1948). The substance was called Auromycine or also known 
as Chlorotetracycline (CTC). Terramycine was isolated in 1949 (Finlay et al., 1950) by
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fermentation of the actinomycete, Streptomyces rimosus. The parent tetracycline (TC) 
itself was formed by catalytic hydrogenolysis of aureomycin in 1953 (Boothe et al., 1953), 
subsequently, this compound was prepared by cultivation of certain strains of 
Streptomyces albo-niger (Anderson, 1955). The first total synthesis of a TC derivative was 
done in 1962 (Conover et al., 1962). This compound is now called sancycline. Other 
members of the family with R2 or R4 = OH are much more difficult to synthesise because 
they are very sensitive to acid and base (Muxfeldt et al., 1979). This synthesis is linear, i.e. 
each step follows the previous one (D—>A method); the authors did not report their percent 
yield, but if each of the 18 steps had produced an 80% yield, the overall yield would have 
been only 1.8%.
Because of the low yield and the high costs most TCs derivatives are normally produced 
from the fermentation products by a semi-synthetic route (Nelson et al., 2003). Although 
this approach has been somewhat effective, it is limited be the capacity of the TC skeleton 
to undergo chemical transformation (Martell and Boothe, 1967; Stephens et al., 1958). 
Recently Myers and co-workers report an efficient new pathway for the “total synthesis” of 
TCs with extraordinary flexibility, providing practical access to >50 TCs derivatives that 
would be difficult or impossible to prepare through the semi-synthetic approach (Sun et al., 
2008a). This strategy involves the parallel preparation of the left (D ring) and the right (A 
and B ring) and the re-unification of these fragments close to the end of the synthesis, with 
concomitant formation of the central C ring (AB plus D method) (Charest et al., 2005; Sun 
et al., 2008a). Many of these new TCs would be very difficult or impossible to obtain 
through semi-synthesis. This finding could serve as a powerful discovery engine, but the 
clinical relevance of these derivatives remains to be seen.
1.6.2 Physical and chemical properties
Tetracycline is yellow, crystalline, odourless substance. Looking at the bonding properties 
of the ring carbon atoms of TC some statements about the conformational flexibility of the
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molecule can be given. The aromatic D-ring is stiff. The flexibility of Ring B and C 
depends on the protonation of the 11, 12-p-dicarbonyl system and ring A is the most 
flexible. The conformation of ring A depends on the substitution with functional groups 
and their charges, as well as the capability to form H-bonds with functional groups on the 
BCD-chromophore. The latter is particularly true for the C4-dimethylamino group. The 
carbon atoms 4, 4a, 5, 5a, 6 und 12a are asymmetric and the molecules are separated by 
two characteristic chromophores: the A-chromophore and the BCD-chromophore. The 
UV-spectra of Tetracycline are pH dependant. The BCD-chromophore absorbs at 225, 285, 
320 and 360 nm, whereas the A-chromophore absorbance is at 260 nm (Durckheimer, 
1975). Hence the band at 275 nm is composed of the contribution of the different 
chromophores. OTC and TC have additionally a band at 360 nm, CTC at 370 nm, to which 
only the BCD-chromophore contributes (Durckheimer, 1975). The free bases of the TCs 
make the molecule hardly soluble under physiological condition (1 mg/ml) (Durckheimer, 
1975). TCs are amphoteric, because of the acidic groups and the basic dimethylamino-rest 
which let them form water-soluble, stable salts with bases and acids. Especially TC- 
Hydrochloride shows a high stability as a solid substance. The pH-value of the water 
solution is between 2-3 (Durckheimer, 1975). The free bases and hydrochlorides are well 
dissolved in alcohols and less soluble in organic solvents. TCs are instable in aqueous 
solution and are losing rapidly their antibiotic activity. The stability depends to a great 
extend on the pH-value and temperature and differs among the derivatives (Liang et al., 
1998; Naggar et al., 1974a; Naggar et al., 1974b). Under acidic and neutral condition TC 
and OTC are more stable than CTC, whereas OTC is more stable under alkaline condition. 
The determination of the apparent acidity constants of TCs and the deduction of the 
macroscopic and microscopic pKa-values (Fig. 1-13) for the various functional groups is a 
valuable tool to predict the efficacy. The first deprotonation step of the cation, upon pH 
titration from pH 2 to pH 11, involves the tricarbonyl system composed of C1-C3 and Cam
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(acid functional group a, pKa ~ 3.3). In a next step the P-keto-enol system at Cl 1 and C12 
is deprotonated (acid functional group c, pKa ~ 7.7) followed by a proton removal at the 
dimethyl ammonium group attached to C4 (basic functional group bH+, pKa ~ 9.6) 
(Colaizzi and Klink, 1969; Schmitt and Schneider, 2006; Schmitt et al., 2007). Duarte et al. 
allocated an additional pKa value of 12 to the phenol group at CIO atom (Duarte et al., 
1999). Nevertheless, because of the varying substitution in the TC derivatives, the acidity 
constants of the molecules in a certain state of protonation can vary by several orders of 
magnitude depending on its actual conformation (geometry, tautomerism, hydrogen- 
bonding pattern).
CH.
HO CH
6a 5a
12a
|am
10a 11a
TcHt  ^  TcHl + H+ ^  TcH~ + 2H+ ^  TcH2~ +  3H
Fig. 1-13: Acidic functional groups of Tetracycline a) C2 tricarbonyl system b) C4 Dimethylamino
group (here bH+) protonated c) Keto-Enol-groupe of the BCD (Schmitt and Schneider, 2006).
NMR, CD and molecular dynamics studies suggested that two major conformations named
“twisted” and “extended” (Fig. 1-14) exist in solution (Aleksandrov and Simonson, 2009;
Lanig et al., 1999; Mitscher et al., 1968; Mitscher et al., 1972). These conformations differ
in the relative positions of the carbon atoms Cl-Cl2a and are governed by the various
functional groups, solvent composition, metal complexation and pH (Mitscher et al., 1972).
For instance NMR experiments combined with spectral data calculated using density
functional theory suggest that tetracycline always prefers the extended conformation but
that 5a,6-anhydrotetracycline exists in water as a mixture of the two eonformers and in
chloroform exclusively in the twisted conformation (Lanig et al., 1999). Schmitt et al.
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confirmed the conformational changes during the pH titration by absorbance and 
fluorescence spectroscopy. Interestingly, they found that, if the crystalline material is 
dissolved directly at pH 2 or pH 11, the TC is in the extended conformation, but changes to 
twisted if the pH is changed from pH 2 to pH 11 (Schmitt and Schneider, 2006; Schmitt et 
al., 2007). Possibly the conformation influences the pharmaco-kinetic properties of 
tetracycline.
Fig. 1-14: The various structures of TCs A: extended B: twisted.
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1.6.2.1 Complex formation
TCs are able to a reversible formation of antibiotic inactive complexes with anions and 
cations as well as with low- or high molecular substances (Durckheimer, 1975) (Table 1-4)
Table 1-4: Complexing agents for TCs (adapted from (Durckheimer, 1975).
Metal cation Fe2+/3+, Cu2+, Ni2+, Co2+, Zn2+, Mn2+, Mg2+, Ca2+, 
Be2+, A13+, Zr3+, Zr4+
anions Phosphate, citrate, salicylate,p-hydroxybenzoate, 
saccharin anion
Natural compounds caffeine, urea, thiourea, polyvinylpyrrolidone
Macro molecular substances Serum albumin, lipoprotein, globuline, RNA
Whereas the hydrophobic TC, DC and MC scarcely form complexes, the hydrophilic 
compounds OTC, TC and RTC form a strong complex (Kuschinsky and Lullmann, 1981). 
The stoichiometry ratio between the metal and the ligand (TCs) depends on the cation, its 
charge, and pH-value of the solution (Albert, 1953; Albert and Rees, 1956; Novak-Pekli et 
al., 1996). Below pH 3 no complexation is observed. The phenol-diketon-system of the 
BCD-ring binds a cation between pH 3 and 7.5. An additional cation can be bound 
between the dimethylamino-group and with respect to the former group cis-12a-Hydroxy- 
group above pH 7.5. In case of Anhydrotetracyline, 4-epi-tetracycline and iso-TC 
(involved in degradation and conversion of TC) are forming only a 1:1 complex (De 
Almeida et al., 1998; Durckheimer, 1975). OTC and metal cation form a chelat using 
ligand at 5 and 12a-Hydroxy-group above pH 7. The metal complex shows a characteristic 
UV spectra with a maxima at 275 nm and concentration dependant change between 370 
nm and 390 nm. Wessels et al. found two isosbestic points during the Ca2+ titration, where 
the extinction coefficient doesn’t change (Wessels et al., 1998). Furthermore, the TC 
fluorescence is sensitive to complexation (Schneider et al., 2003). That’s why metals are
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used for the qualitatively and quantitatively determination of the TC concentration. TC 
forms weak complexes with anions like phosphate and citrate, which increase the solubility 
of TC. The reversible binding capability of TC to macromolecules in blood and tissue is of 
great importance for efficacy and pharmacokinetic. Such equilibrium is quantitatively 
difficult to determine. TC binds to albumin, the constituent of the serum, as well as to the 
globulins and lipoproteins. The binding constant depends on pH-value and temperature. 
The effect of serum binding capability to the chemotherapeutic activity is up to date 
unknown (Durckheimer, 1975).
1.6.2.2 Rearrangement and Degradation
TC undergoes a series of rearrangement and degradation reaction depending on 
temperature and pH-value. There are distinct differences between the derivatives of TC 
(Halling-Sorensen et al., 2002; Soeborg et al., 2004). The conversion reactions are called 
isomerisation where the configuration changes but the chemical formula is the same. 
Isomerisation is in literature restricted to the alkaline conversion of TC to iso-TC and well 
distinguished to the epimerization and keto-enol-tautomerism. Besides the rearrangement 
the compound can be degraded by dehydration.
1.6.2.3 Epimerization
In weak acidic solution between pH 2 and 6 TC undergoes an isomerisation at C4 atom. 
This kind of configurationally changes, where more than one asymmetric C-atom is 
involved are called epimerization (Bryan et al., 1992). Epimerization follows a first order 
reaction mechanism. It is reversible and is catalyzed by phosphate, citrate and multivalent 
cations (McCormick et al., 1957). The equilibrium and the reaction velocity depend on the 
pH-value and the epimerization rate lies between 40% and 68%. Whereas below pH 1.5 no 
epimerization is observed, the epimerization rate increases with increasing pH-value 
(Hussar et al., 1968; Martinez and Shimoda, 1989; Remmers et al., 1963).
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The epimerization products usually have a higher solubility compared to the parent 
compound and are more stable under alkaline and acidic condition (Brunner and Machek, 
1962). Furthermore the configurationally changes have great impact on the antibiotic 
activity. Several publication described that the epimer has a by 90-99% lower antibiotic 
efficacy. This raises the question whether or not the epimer is active or the re- 
epimerization of the compound is responsible for this observation (Brunner and Machek, 
1962; Hussar et al., 1968).
The epimers show a significant change in the UV-spectrum due to the chromophore A 
contribution. This difference was used to determine the amount of epimers in a solution by 
CD-spectroscopy (Brunner and Machek, 1962; McCormick et al., 1957).
1.6.2.4 Isomerisation
The alkaline treatment of TC leads to the C-ring opening by the hydroxyl-group at C6 
attacking position 12 and the formation of phthalate structure (Brunner and Machek, 1962; 
Durckheimer, 1975). This reaction is irreversible. Whereas TC and OTC form isomers 
above pH 9-10, CTC forms the iso-CTC already at pH 7. These iso-TCs can rearrange to 
epimers under weak acidic condition.
The formation of iso-TCs is accompanied by the pH-dependant changes of the UV- 
absorption between 320-380nm (Kennedy et al., 1998). UV-absorbance of iso-TC is only 
present under alkaline condition and the fluorescence increases significantly and is used for 
analytical determination of TC (Blanchflower et al., 1989; Zhao et al., 1997).
1.6.2.5 Keto-Enol-Tautomery
TCs are able to form 64 distinct tautomeric forms depending on the pH-value (protonation 
state) and the polarity of the solvent. Duarte et al. demonstrated that the fully protonated 
state contains 9 structures (Duarte et al., 1999), whereas the equilibrium between these 
tautomers determine the real structure of the compound. Tautomeric rearrangement take
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place on the C1-, C2- and C3-atom of the A-ring, on CIO-, ClOa-, and Cl 1-atom of the 
CD-ring, and on Cl 1-, Cl la, and C12 atom of the BC-ring. Naidong et al. separate the first 
time tautomeric forms by chromatography and confirmed by NMR the changes in the Cl 1- 
, Cl la- and Cl 2-atom (Weng et al., 1990). Basically the keto-enol-tautomerism is 
catalysed by acids and bases.
1.6.2.6 Dehydration
TCs containing a hydroxyl-group at C6-atom like CTC lose easily water below pH 1.5 and 
the C-ring gets aromatic (Durckheimer, 1975). This elimination reaction takes place 
because of the /nms-position of the tertiary hydroxyl-group at C6 to the H-atom at C5a. 
This is an irreversible reaction second order. These formed Anhydro-TCs are able to form 
epi-Anhydro-TCs under weak acidic condition.
The changes in the BCD-ring upon dehydration affect the UV-absorption spectrum which 
shows a lower intensity in the wavelength range between 320 and 380 nm compared to the 
unmodified compound.
1.6.2.7 Pharmacology o f the TCs
The different TCs derivatives show differences in enteral resorption, in plasma protein 
binding, elimination velocity, the expulsion pathway and their capability to form 
complexes (Zhanel et al., 2004).
CTC, TC, OTC and DMCTC are not fully absorbed and show low plasma protein binding 
(Schnappinger and Hillen, 1996; Zhanel et al., 2004). At variance the hydrophobic DC and 
MC show a full enteral absorption, a higher protein binding, a better diffusion in the tissue 
and a longer effective period (Zhanel et al., 2004). The complex formation capability can 
block the absorption and also leads to the accumulation of a potassium-phosphate-complex 
in the tissue which is containing an abundant amount of Ca2+ ions, as bones and teeth.
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Other characteristics like half time and protein binding are summarised in Zhanel et al 
(Table VII)
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Two decades ago it was proposed that Alzheimer’s disease was a consequence of the 
abnormal aggregation and deposition of the Ap protein in the brains of affected 
individuals. Subsequent therapeutic approaches to halting the progression of the disease 
preventing the aggregation or oligomerisation, has attracted much attention. To date, while 
many compounds show effectiveness at inhibiting amyloid beta aggregation in vitro, all 
have failed to produce any promise of clinical efficacy. Nevertheless TCs have shown their 
potential as drugs for AD treatment. Besides of their possible anti-amyloidogenic effect, 
they are in general neuroprotective, interfering with various biochemical pathways in the 
brain. Since some inconsistency is observed among the scientific literature about the anti- 
amyloidogenic effect, the aim of the studies reported in this thesis is to further clarify the 
mechanism of action. This will be done as follows:
1) to investigate the lack of reproducibility of sample preparation and formation of amyloid 
structures by synthetic Ap peptides, found in initial experiments and by review of the 
literature.
2) then to devise methods of preparation of the Ap peptides in different well-characterised 
state, which can then be induced to aggregate (polymerise) to give a consistent product and 
with well-defined and reproducible kinetics.
3) to use a range of biophysical methods (SPR, AFM, CD etc) for the characterisation of 
starting materials and products in terms of structure of products, and conformational 
properties of the starting material.
4) to establish methods for making well-defined amyloid seeds and to use them for the 
kinetic study of the addition of Ap monomers.
5) to examine the fluorescence of TCs and CD in the presence of amyloid peptides, and to 
evaluate the ability of TCs to monitor amyloid formation because of the structural changes 
of the compound.
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6) to verify the possibility of TCs as inhibitors of in vitro amyloid formation, and to 
investigate the mechanism in terms of kinetics and structure.
7) to perform in vivo studies of plaque formation in APP/PSltg mice to evaluate the
magnitude of any inhibitory effect of the presence of a typical TC.
8) to seek a coherent explanation of inconsistencies in previous reports compared to the
work of this thesis.
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3.1 Material
All the chemicals in this work were purchased from Sigma-Aldrich (Italy) and used as 
such. Variations are explicitly addressed. Standard amino acids were kindly provided by 
Flamma inc. (Italy). Aqueous solutions were prepared by using double distilled ultrapure 
water (Milli-Q, Millipore)
3.2 Peptide Synthesis
3.2.1 Automated peptide synthesis
The solid state synthesis (Merrifield, 1965) of Ap fragments were mainly done on a ABI 
433A automated peptide synthesiser (Applied Biosystems, Foster City, US). Fmoc group 
as a a-amino protecting group and the producer supplied FastMoc 0.10 mmol chemistry 
option was used to synthesise the peptide chain. All automated synthesis steps were done 
at room temperature.
The first amino acid were attached to the linker on a TentaGel-resin (0.26 mmol/g, 
Novabiochem) by the DIC/NMI method (Coin et al., 2008) in DCM (5 ml) for lx l h. For 
this 155 mg Fmoc-Ala-OH (5 eq, 0.5 mmol) in case of depsi-Apl-42, 77.4 pi DIC (5 eq, 
0.5 mmol) and 31.7 pi NMI (4 eq, 0.4 mmol) were used. The loading was checked by
quantifying the amount of Fmoc after the removal from the protected amino acid (Gude et
al., 2002).
Despite the guest host depsi-Ap 14-24, which was synthesised on NovaPEG Rink amide 
resin (loading = 0.44 mmol/g, Novabiochem), the C- and N-terminus were free. The Fmoc 
group were removed in a 22% piperidine/DMF (v/v) solution for 10 min. The formation of 
the peptide bond was established using 10 fold excess of the reagent compared to the 
peptide chemistry (1 mmol) and reaction mixture containing either TBTU or HCTU 
(Novabiochem) as coupling reaction and DIEA were left for 9 min under continuous 
stirring.
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The Depsidipeptide Boc-Ser(Fmoc-Gly)-OH (Novabiochem) and the ester bond formation 
between Boc-Ser-OH and next incoming amino acid in depsi-Ap 14-24 were manual 
introduced. The remaining amino acids were coupled with the automated synthesiser. The 
peptide bound to the dry resin was cleaved and de-protected with reagent R (Huang and 
Rabenstein, 1999) for 3 h. The peptide was precipitated into cold diethylether and washed 
for three times. Purification was done with semi-preparative HPLC (C4 Water Symmetry 
19x150 mm) using the solvent system (solvent A: H20 + 0.1 TFA, 
solvent B: H20/CH3CN 98:2 + 0.08 % TFA). Purity was determined under similar 
condition using an analytical C4 Waters Symmetry (4.6x150 mm) column. Finally, the 
molecular mass of the final products were analyzed with a MALDI-TOF mass 
spectrometer (Bruker).
3.2.2 Manual peptide synthesis
Manual peptide synthesis were done for the first amino acid coupling and the introduction 
of the depsi-dipeptide or the ester bond formation. For this the resin was put into a fritted 
polypropylene syringe. The dipeptide building block was dissolved in DCM containing 
DIC/HOBt. The completeness of the reaction was checked by the Kaiser-Test (Chan et al., 
2000; Kaiser et al., 1970). In case of the guest-host system depsi-Ap 14-24 the ester bond 
between Boc-Ser-OH and the following amino acid was formed on the resin using the 
DIC/NMI method (Coin et al., 2007). Following are listed all the necessary steps for the 
manual solid state peptide synthesis.
3.2.2.1 Condition for the various steps o f peptide synthesis
Table 3-1: Condition for first coupling to Rink amide resin using guanidium based reagents.
Fmoc-AA-OH 5 eq
TBTU, HBTU 5 eq
DIEA 10 eq
in DMF or NMP 1 x or 3 x 30 min on a stirring wheel
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Table 3-2: Condition for first coupling to NovaPEG resin and ester bond formation between Boc-Ser- 
OH and the following AA on the resin by DIC/NMI method.
Fmoc-AA-OH 5 eq
DIC 5 eq
NMI 4 eq
in DCM (with a minute amount o f DMF to dissolve the AA) 1 x 
3 h on a stirring wheel
Table 3-3: Condition for coupling of depsi-Dipeptide by DIC/HOBt method.
depsi-dipeptide 2.5 eq
DIC 2.5 eq
2 h o f pre-activation in DCM (with a minute amount of DMF to 
dissolve HOBt), reaction 2 x 2 h on a stirring wheel
Table 3-4: Condition for Fmoc deblocking.
Piperidine 20%  in DMF (v/v)
1x5 min and 1x10 min
3.22.2 Kaisertest (Kaiser et al., 1970)
This test recognises free primary amines and gives an easy qualitative measure about the 
completeness of the peptide bond formation. For this a small amount of resin is taken, and 
washed with ethanol. After 10 pi of every solution (80% phenol in ethanol, KCN in 
water/pyridine, 6% ninhydrine in ethanol) of the Kaiser-Test kid (Fluka) is added, mixed 
and incubated at 120°C for 5 min. The resin beads and the solution turn dark blue when 
free primary amine is present.
3.2.2.3 Determination o f resin loading
The loading was checked by quantifying the amount of Fmoc removed from 10 mg of resin 
beads weighted into a 1.5 ml polypropylene vial (Eppendorf) (Gude et al., 2002). After 
washing the resin with DCM the residual solvent was evaporated (concentrator 5301, 
Eppendorf) for 15 min. Then the resin was dissolved in DMF and left under continuous 
movement on a stirring wheel for 30 min. After this 20 pi of DBU was added affording a 
solution of 2% DBU/DMF (v/v) and left under stirring for other 30 min. 500 pi of the 
solution was diluted in 50 ml pure AcN. A reference solution is prepared in the same 
manner but without addition of the resin. The amount of Fmoc-group was quantified by 
absorbance measurement at 294 nm (extinction coefficient 8794M-lcm-l) using a 
UV/VIS-spectrometer (Lambda 19, Perkin Elmer) in a 1 cm quartz cuvette.
51
Material and Methods
3.2.3 Kinetics of native sequence formation
Around 1 mg/ml of depsi-peptide was dissolved in the clicking solution. The reaction was 
stopped by acidification pH 2 with aqueous 0.1 M HC1 at various time points. This solution 
was injected onto a HPLC column (C4 Water Symmetry 19x150 mm) using the solvent 
system (solvent A: H20 + 0.1 TFA, solvent B: H20/CH3CN 98:2 + 0.08 % TFA).
3.3 In-vitro binding and kinetics offibril formation studies
3.3.1 Thioflavine T (ThT) fluorescence
3.3.1.1 ThT measurements
ThT measurements were done using the spectra fluorimeter LS 50 B (Perkin Elmer). For 
this the 10 pL of peptide solution was mixed with 400 pL of 50 pM of ThT in 50 mM 
phosphate buffer, pH 7.4. The dye was excited at 440 nm and the emission was taken at 
480 nm.
3.3.1.2 In-situ ThTkinetic experiments
Every sample containing 20 pM of ThT was measured in triplicate and incubated on a 
plate reader (M200 Infinity, Tecan) in a 96 wells containing black plate with flat 
transparent bottom (Comig). The plate was orbitally (5 mm) shaken for 10 s every 10 min 
and ThT was excitated 440 nm and the emission was measured at 495 nm.
3.3.2 Circular Dichroism (CD) analysis
Circular Dichroism experiments were mainly used to determine the secondary structure of 
the various preparations of Ap fragments. This includes the investigation and 
reproducibility of the initial solution as well as the time dependant changes in secondary 
structure. The far-UV CD spectra (190-260 nm) scans were obtained on a J-810 
spectropolarimeter (Jaso) at varying temperature which was maintained by a Pelletier 
heating system. The solution was put into a 0.1 mm path length quartz cell and the scan 
speed was chosen depending on response time and bandwidth as suggested by Kelly et al.
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(Kelly et al., 2005) (Table 3-5). The buffer spectrum was subtracted and the raw CD values 
converted to mean molar ellipticity.
Table 3-5: Parameters for CD spectrum scan and timecourse experiment to monitor the changes at 
215 nm.
Parameter Setting Parameter Setting
Sensitivity lOOmdeg Sensitivity 100 mdeg
Wavelength 260-190 nm Wavelength 215 nm
Data pitch 0.5 nm Data pitch 5 s
Scan speed 100 nm/min Response 8 s
Response 0.5 s Bandwidth 1 nm
Bandwidth 1 nm Time lOh
Accumulation 10
The random state to p-sheet conversion was determined by repeated scans at various time 
points during the incubation. The P-sheet characteristic CD-values at 215 nm were then 
extracted from the scans and used for kinetic evaluation. In some cases however kinetic 
data were obtained by continuously measuring CD value exclusively at 215 nm (Table
3-5). In some experiments the magnetic stirrer incorporated in the pelletier heating system 
was used to move the solution with small magnetic bead (3 mm) in a 1 cm cuvette. Since 
the bead was relatively small compared to the cuvette diameter large values of agitation 
speed was used (up to 1330 rpm)
3.3.3 CD spectra of Doxycycline (DC) depending on pH
DC was dissolved in water to give a concentration of 20 mM. This solution was diluted
into 500 ml of 20 mM Stenhagen buffer (20 mM citric acid, 20 mM boric acid and 20 mM
phosphoric acid) to give 20 pM DC which were adjusted to the desired pH of two by
adding either 10MHC1 or lMNaOH. In order to minimise the dilution effects,
1 MNaOH used as titration agents were added with a 100 pi Eppendorf pipette. The pH
step width was ApH ~ 0.33. After the stabilization of the signal when ApH/At < 0.01/min
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was reached, a sample of the solution was transferred to a 1 cm and the CD spectra taken 
(500 nm - 200 nm) at 25°C
3.3.4 Titration of Ap assemblies with ligands (TCs) by following changes in the CD 
bands upon ligand binding
Since TCs are rich in the CD spectra any changes in the structure or perturbation of the 
electronic configuration due to binding should be visible. In these experiments the TCs 
concentration is changed whereas the concentration of the Ap assembly is constant. For 
this two solutions are prepared, where one contains the Ap (solution 1) and the other the 
ligand + Ap fragment (various species) (solution 2). An example is given in following 
table (Table 3-6), where the concentration of the TCs concentration is assumed to be 
200 pM:
Table 3-6: Pipetting protocol to determine the changes in the CD spectrum upon ligand titration.
Vol. Solution 1 
(pl)
Vol. Solution 2 
(pl)
Vol. sum 
(pl)
ligand
concentration (pM)
100 0 100 0
100 25 125 40
100 50 150 66.67
100 75 175 85.71
100 100 200 100
3.3.5 Fluorescence Microscopy
Fibrils were formed under acidic condition at a concentration of 150 pM and diluted into 
phosphate buffer pH 7.4 in the presence of various concentration of TC, ThT or X-34 
(Ikonomovic et al., 2006). A drop was put onto a cover glass and immediately observed 
under the microscope (Olympus). Two filters were used (FI: excitation 330-385 nm and 
emission detected at wavelength greater than 420 nm for TCs; F2: excitation 400-440 nm, 
emission >475 nm) for ThT and X-34.
3.3.6 Atomic force microscopy (AFM)
Sample was diluted with water to a final concentration of 10 pM and incubated for 0.5-2
min on a freshly cleaved mica disk. Then, the disk was washed with water and dried under
gentle nitrogen stream. After, the sample was mounted onto a Multimode AFM with a
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NanoScope V controller (Veeco/Digital Instruments, Santa Barbara, CA) operating in 
Tapping Mode using standard phosphorous doped silica probes (Veeco). The scan speed 
was 1 Hz.
3.3.7 Size exclusion chromatography (SEC)
SEC was done on an FPLC apparatus (Biologic FPLC system, Biorad) equipped with a 
precision column pre-packed with Superdex 75 resin, with a separation range of 3-70 kDa 
(GE Healthcare). The mobile phase flow rate was set at 0.5 mL/min and the elution peaks 
were detected at 214 and 280 nm UV absorbance. The mobile phase was 25 mM phosphate 
buffer (pH 7.4). The column was calibrated using insulin chain B (3.5 kDa), ubiquitin (8.5 
kDa), ribonuclease A (13.7 kDa), carbonic anhydrase (29.0 kDa), ovalbumin (43.0 kDa) 
and bovine serum albumin (67.0 kDa). The void volume was determined with Blue 
dextrane 2000 (2000 kDa) and each peptide solution was injected at a final concentration 
of 20 pM in a volume of 100 pL.
3.3.8 Surface Plasmon Resonance (SPR)
The SPR apparatus used for these studies (ProteOn XPR36, Biorad) has six parallel flow 
channels that can be used to uniformly immobilise strips of six “ligands” on the sensor 
surface. The fluidic system can automatically rotate 90° so that up to six different analytes 
can be injected, allowing to monitor simultaneously up to 36 individual molecular 
interactions in a single run on a single chip (Bravman et al., 2006). Apl-42 monomers and 
fibrils (either sonicated or not) were immobilised in parallel flow channels of the same 
GLC sensor chip (Biorad) using amine-coupling chemistry, as previously described 
(Cannon et al., 2004). Briefly, after surface activation the peptide solutions (10 pM in 
acetate buffer pH 4.0) were injected for 7 min at a flow rate of 30 pl/min, and the 
remaining activated groups were blocked with ethanolamine, pH 8.0. The final 
immobilization levels were about 3200 and 2300 Resonance Units (RU, 1 RU=1 pg 
protein/mm2) for fibrils and monomers, respectively. A “reference” surface was always
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prepared in parallel using the same immobilization procedure but without the addition of 
the peptide.
After the 90° rotation of the fluidic system, analytes (Apl-42 monomers, the anti-Ap 
antibody 6E10, or Congo-Red specifically recognizing p structures) were then injected 
over immobilised Api-42 species and reference surface, for 2-5 min at a flow rate of 30 
pl/min. At the end of the injection, the dissociation reaction was followed for at least 10 
min. The running buffer, also used to dilute analytes, was phosphate-buffered saline 
containing 0.005% Tween 20, pH 7.4 (PBST, Biorad). All these assays were done at 25 °C.
The sensorgrams (time course of the SPR signal in RU) were normalised to a baseline 
value of 0. The signal observed in the surfaces immobilizing the peptides was corrected by 
subtracting the response observed in the reference surface. Parallel injections of vehicle 
alone allowed correcting for binding-independent responses (i.e. drift effects). The 
resulting sensorgrams were globally fitted using at first the Langmuir equation modelling 
the simplest 1:1 interaction. Api-42 fibril growth by monomers addition was fitted by a 
three-step conformational change model similar to that previously described for Apl-40 
(Cannon et al., 2004). The nonlinear least squares data analysis program CLAMP was used 
for the optimization problem (Myszka and Morton, 1998).
3.4 Toxicity of Ap assemblies
3.4.1 Preparation of primary hippocampal neurons
Hippocampus was dissected from 2 days old rat pups and incubated with 200 units of 
papain (Sigma Aldrich) for 30 min at 34°C, treated with trypsin inhibitor (Sigma Aldrich) 
and mechanically dissociated. Neurons were then plated on 96-wells plate pre-coated with 
25 j-ig/ml poli-D-lysine and maintained in B27/neurobasal (Life Technologies, 
Gaithersburg, MD) supplemented with 0,5 mM glutamine, 100 U/ml penicillin and 100 
pg/ml streptomycin. Ap peptides were added to cells after 12 days in culture, when 
neurons are mature and differentiate.
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3.4.2 MTT assay
Cell viability was analyzed by measuring the conversion of the yellow, water-soluble 
thiazolyl blue tetrazolium bromide (Sigma Aldrich, #M5655) to the blue, water-insoluble 
formazan. Data are presented as the percentage of survival relative to untreated control 
cultures. All experiments were repeated at least three times using indipendent culture 
preparations.
3.5 Treatment of APP/PS1 tg mice with DC
The APP/PSltg mice were treated at 15 months of age for 20 days with 10 mg/kg/ml of 
DC, intraperitoneally. The plaque deposit after DC treatment compared to a control 
experiment (physiological solution) was examined. APP/PSltg mice were IP anesthetised 
with equithesin and intracardially perfused with 4% PAF and their brains removed and, 
after sucrose cryo-protection, frozen and stored at -80°C. Thirty pm brain sections were cut 
using a Leica cryostat and left free-floating in PBS IX in 24-well plates. After the 
treatment with 1% H202(5 minutes, RT) and blocking solution (10% NGS in PBS IX; lh 
at RT) the slices were incubated with the 6E10 primary antibody (1:500; Signet; O/N, 
4°C). Primary antibody incubation was followed by that with anti-mouse biotinylated 
secondary antibody (1:200; Vector Laboratories) for lh at RT. Immunostaining was 
developed using the avidin-biotin kit (Vector Laboratories) and DAB/H2O2 reaction.
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4.1 The initial state and sample preparation
A highly reproducible initial state is essential for conducting and comparing kinetic 
experiments. In this chapter we systematically changed the synthesis and preparation 
procedure to obtain a reliable stock solution of Api-40 or Api-42 which then is used to 
prepare various Apl-42 assemblies like initial state, oligomers and fibrils. These 
assemblies are then characterised by various physico-chemico procedures.
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4.1.1 The improvement in reproducibility of the initial state CD spectrum by use of 
depsi-Ap
First we wanted to analyze the structural properties of Apl-40 prepared by conventional 
SPPS. For this, CD spectra of different Apl-40 (synthesised by conventional SPPS) 
preparations were determined. The solution was prepared by dissolution of the peptide 
powder in 10 mM NaOH to give a stock solution concentration of 300 pM and vortexed to 
bring the peptide into solution. Then, the stock solution was diluted to give 30 pM of 
peptide in PB pH 7.4. Fig. 4-1 A shows five spectra from five different preparations. All 
the spectra show statistical coil structure but varied significantly from each other. To 
exclude that the variability comes from the variation in peptide concentration, the 
concentration independent ratio between the CD value at 205 nm and 215 nm was 
calculated. The value of the ratio for Api-40 prepared by conventional SPPS is 1.9 with a 
standard deviation (SD) which demonstrates the irreproducibility of the initial state spectra 
(Fig. 4-1 B). Since extensive vortexing during the dissolution step could be responsible for 
the formation of precipitate which could be responsible for the changes in the initial state 
spectra (O'Nuallain et al., 2006; Teplow, 2006), acetonitrile (AcN) was added to the NaOH 
solution (50 AcN:50 20 mM NaOH) (Bartolini et al., 2007). Beside of the reduction of SD, 
also the ratio decreased to give 1.7 (Fig. 4-1 B) and no extensive vortexing was needed to 
bring the peptide powder into solution. Since AcN induces a-helix formation (Bartolini et 
al., 2007), another route of stock solution preparation without vortexing was needed. For 
this the peptide synthesis strategy was changed. The relatively new depsi-peptide technique 
was utilised (Sohma and Kiso, 2006).
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Fig. 4-1: Preparation of a reliable stock solution and the impact of vortexing
Panel A: Various CD experiments 30 uM A pi-40 synthesis by conventional SPPS in 50 mM PB pH 
7.4 at 37°C to test the reproducibility of the initial state spectrum, for this the peptide powder was 
dissolved in 10 mM NaOH (peptide concentration 300 juM) and vortexed until full dissolution was 
reached, then the buffer was added and spectrum was taken. Panel B: Difference in the quality 
factor of three different preparations (peptide prepared by conventional peptide synthesis, column 
one = powder dissolved in 5 mM NaOH aqueous solution and column two = powder dissolved in 
50:50 AcN:10mM NaOH and the depsi-Api-40 dissolved in 0.02% water/TFA solution. Panel C: 
Comparison of the kinetic of p-sheet formation of in at 37°C, The extensive vortexed (5 min) or not 
vortexed high concentrated basic stock solution was diluted into 50 mM PB pH 7.4 to give 20 pM 
depsi-Apl-42 and incubated in 1 mm cuvette and the CD signal at 215 nm was monitored at 37°C. 
Panel D: ThT value of the depsi-Apl-40/1-42 stock solution (0.02% water/TFA solution) without and 
with the filtration through a 10 kDa cut-off filter. Panel E: Loss of material during the filtration of 
depsi-peptides and after the formation of the native sequence.
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Especially notable is the fact that the ester bond increased the water solubility of Apl-42 
by 100 times and furthermore blocked the aggregation of the peptide if kept under acidic 
condition (Sohma et al., 2004a). The native sequence is obtained by a pH shift at normally 
neutral pH.
Fig. 4-1 B shows an increase in the ratio to 2.6 and very low SD compared to the other two 
procedures. Like during the dissolution of the peptide powder in presence of AcN no 
vortexing was needed. To demonstrate that extensive vortexing is responsible for the 
irreproducibility or even formation of aggregates or precipitates, two different kinetic 
experiments were conducted where the changes of the p-sheet characteristic CD signal at 
215 nm were monitored Fig. 4-1 C. Firstly a basic depsi-Ap 1-42 stock solution (300 pM) 
was prepared and diluted to 20 pM Api-42 to give in PB pH 7.4 and incubated in a CD 
cuvette at 37°C. Secondly a 300 pM basic depsi-Apl-42 stock solution was extensively 
vortexed for 5 min and the kinetic was followed using the same sample condition like in 
the former experiment. Whereas the un-vortexed sample didn’t show a significant change 
in the signal intensity, the vortexed sample immediately changes its value which indicates 
an immediate aggregation and P-sheet formation of the peptide.
After we had established the superiority of depsi-Ap peptide over the peptide synthesised
by conventional methods, all following experiments used the depsi-Ap 1-40 or depsi-Ap 1-
42 where an ester bond is introduced between the Serine at position 27 and Glycine at
position 26. Even though that the introduction of the ester bond in the turn of the monomer
inhibits the intra molecular interaction which favour the aggregation, inter molecular
contacts between two molecules which form fibrillar aggregates as well can’t be excluded
(Tuchscherer et al., 2007). Thioflavine T measurements show that a significant amount of
fibrillar structure is present in the aqueous 0.02 % TFA solution (peptide is still in the
depsi state Fig. 4-1 D) which is slightly higher for the more aggregation prone Apl-42 (5.5
AU) compared to Apl-40 (1.7 AU). Even though that these values are very low, any seed
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present in the starting solution has an impact on the kinetic of fibril formation. That’s why 
the aqueous 0.02 % TFA solution was filtered through a 10 kDa cut-off filter. For this, the 
peptide was dissolved in 0.02 % aqueous TFA at a concentration of around 1 mg/ml and 
was put on a cut-off filter (YM-10, Millipore). After the filtration was completed, the filter 
was washed with 100 pi with the same dissolution solution and filtered again. This was 
repeated once again. After, the concentration was determined and the loss of peptide 
during the procedure calculated. The ThT value was reduced for both Ap variants (Api-40 
= 0 AU and Api-42 = 0.5). Few amount of protein was lost during this procedure. In case 
of Api-40 19.7 % and 42.15 % for Api-42, which is very low compared to the nearly total 
loss of Apl-40 when filtered after the formation of the native sequence 91.5 % (Fig. 
4-1 E).
The concentration of the stock solution was determined by measuring the absorbance at 
280 nm of Tyrosine (ex. coeff. = 1280 cm^M’1) putting the whole filtrate after cut-off 
filtration in 1 cm cuvette. Since the volume was not always sufficient, another technique 
was tried, where only a small amount of stock solution was utilised. Despite the use of the 
conventional colouring test (Bradfourd or BSA), the measurement of the absorbance at 
214 nm was found to be a reliable method. For this the contributions of the amino acids to 
the absorbance and the peptide bonds were summed, like Kuipers et al. suggested (Kuipers 
and Gruppen, 2007) (Table 4-1).
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Table 4-1: Extinction coefficient at 214 nm of various Ap fragments based on the values suggested by 
Kuiper et al. (Kuipers and Gruppen, 2007).
Fragment Extinction coeff.
(M 'W 1)
Apl-40 WT 75053
Api-40 MUT 75064
Apl-42 76976
Apl-6 WT 15274
Apl-6 MUT 15285
The results obtained by measuring the absorbance at 280 nm (63.8 pM) or 214 nm (63.1 
(iM) of Apl-40 are nearly identical, only that the variability at 214 nm is slightly higher 
(Fig. 4-2).
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Fig. 4-2: Comparison of concentration determination of depsi-Api-40 via absorbance measurements at 
214 nm and 280 nm
Filtered Depsi-peptide in aqueous 0.02% TFA solution was put into a 1 cm cuvette and the 
absorbance was measured at 280 nm. To measure the absorbance at 214 nm 20 pi o f the peptide 
solution were diluted in 700 pi aqueous 0.02 %  TFA solution and the value taken when the stability 
of the value was reached after various homogenization steps by moving the solution with a 100 pi 
pipette.
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4.1.2 The initial state of various Ap fragments
Ap 1-40/1-42 are mainly unordered (statistical coil) structured peptides (Roychaudhuri et 
al., 2009). This was confirmed by measuring the initial state spectrum of the two sequences 
in PB pH 7.4 at 37°C (Fig. 4-3 A). Nevertheless the additional two amino acids in Apl-42 
induce a small difference which is also visible if the ratio CD(2 0 5 nm/2 i5 nm) between the 
fragments is compared (Api-40 = 2.7 and Api-42 = 2.3) (Fig. 4-3 B). This is probably due 
to the increase in P-sheet secondary structure of the monomer, which is demonstrated by 
the difference spectra between Apl-40 and Apl-42. The shape of the curve resembles a p- 
sheet spectra with a minimum at around 215 nm (Fig. 4-3 C).
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Fig. 4-3: The initial state of A pi-40 compared to A pi-42 in CD.
Panel A: Initial state CD spectra of 30 pM Apl-40/1-42 in 50 rnM PB pH 7.4 at 37°C. Panel B: Ratio 
of the CD values at 205/215 nm for Api-40/1-42. Panel C: difference spectrum CD (l-40)-C D  (1-42).
Since mutations in a peptide sequence can alter the secondary structure of a peptide, the
initial state CD spectrum of Api-40 MUT of the recently discovered recessive mutation
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(A2V) was measured. No such differences between the initial CD spectra were discovered, 
since both spectra Api-40 WT and Apl-40 MUT (Fig. 4-4 A) and the two hexapeptides 
Apl-6 WT and Api-6 WT of the N-terminus (termini free) (Fig. 4-4 B) are super- 
imposable. The hexapeptides contain a higher amount of unordered structure than the Apl- 
40 peptides, which can be seen by the maximum at 220 nm (Fig. 4-4 B).
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Fig. 4-4 : The initial state of Api-40 WT compared to A pi-40 MUT.
Panel A: CD spectra of 30 pM A pl-40 WT/MUT in 50 mM PB pH 7.4 at 37°C. Panel B: Comparison 
of the CD spectra of 200 pM Ap 1-6 WT/MUT in 50 mM PB pH 7.4 at 37°C.
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4.1.3 Native peptide formation: slightly basic condition permits the preparation of 
high concentrated Ap stock solution
Normally the native sequence is obtained from the depsi-peptide at neutral pH. This takes 
around 2 h at room temperature or 15 min if the migration takes place at 37°C (Taniguchi 
et al., 2009). Drawback, especially in the case of Apl-42, is that, a stock solution 
concentration higher than 50 pM, the peptide immediately starts to form aggregates (Fig. 
4-12 D). Since it is well known that basic condition stabilises and retards the Ap peptide 
aggregation, we wanted to optimise the clicking condition by increasing slightly the pH, 
keeping in mind that hydrolysis of the ester bond could be an unwanted side reaction of 
this procedure. First we investigated the migration in 50 mM ammonium solution (Fig. 
4-5 A) where after the indicated time points a aliquot was taken and acidified with some 
drops of 0.1 M HC1 solution and separated by an analytical HPLC. Fig. 4-5 A shows the 
changes in the HPLC trace. The retention time increases by one minute for the native-Apl- 
40 (clicked) and the migration is completed after 30 min. The hydrolysis of the ester bond 
under basic condition produces two fragments which elute after 28 and 31 minutes (Fig. 
4-5 B). The amount of these fragments is increased when 50 mM NaOH solution is used 
for the native sequence formation. Under this condition the purity of the peptide solution 
compared to the full length Api-40 peptides drops under 95% (see Fig. 4-5 C). But most of 
the experiments require purity higher than 95 % we tried various ratios of the two bases. 
We found that the ratio smaller than 1:2 (NaOH to ammonium solution) is enough to gain 
the desired purity (see Fig. 4-5 C). Nevertheless, we used a ratio of 1:3 for the preparation 
of the native peptide sequence for all our experiments. Under this condition the migration 
is finished after 5 min at room temperature (Fig. 4-5 D). The fragmentation could be 
further reduced when smaller temperatures were used (e.g. on ice). But at the same time 
the incubation time must be increased since the migration kinetics is slowed down (data 
not shown). The exact procedures for sample preparation and native sequence formation 
taken from the results in the last paragraphs 4.1.1 - 4.1.3 are summarised in 7.3.
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Fig. 4-5 Formation of the native sequence or the art of clicking.
The depsi-peptide A pi-40, originally in TFA 0.02%, was switched. Panel A: 50 mM ammonium  
solution, pH > 10.5 at RT. At the indicated time points, aliquots were taken and the switch reaction 
was stopped by dilution in 0.1M HC1 solution. The amount of the various forms were determined by 
HPLC measurement, using an analytical C4 Waters Symmetry (4.6x150 mm) column (solvent A: 
H 2 0  + 0.1 TFA, solvent B: H 20/CH 3CN 98:2 + 0.08 % TFA). The area under peak was used to 
calculate the fractions of the different Ap forms. Panel B: Formation of hydrolysis products in 50 
mM ammonium solution or aqueous NaOH (50 mM) solution monitored by HPLC. Panel C: Purity 
in percent of the full length Api-40 peptide solution depending on the ratio NaOH/ammonium  
solution. The purity was calculated determining AUC of Api-40 peak compared to the overall area. 
Panel D: Timecourse of native peptide formation in 20 mM NaOH/ammonium (1:3) expressed in 
percent.
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4.1.4 Preparation and characterization of specific Apl-42 assemblies (initial state, 
oligomers, fibrils)
The preparation of homogeneous peptide solution containing specific assemblies is 
essential for the investigation of the binding capacity of various ligands. For this we firstly 
prepared a solution, which was obtained shortly after formation, of native sequence with 
the aim to have the peptide at its very initial state. The other two solutions were prepared 
following the protocols described in the literature to obtain oligomers (Ap derived 
diffusible ligands or ADDLs, (De Felice et al., 2008; Lambert et al., 1998)) or fibrils (Stine 
et al., 2003). We then used AFM, ThT, CD and SEC to analyze and compare the Apl-42 
species present in these solutions. The results shown in Fig. 4-6 confirmed that the fresh 
peptide at its initial state was in random structure (CD), with negligible binding of ThT, no 
evident bigger assemblies by AFM and a single peak by SEC. The single peak in SEC at 
30 min corresponds to a molecular weight of 12.3 kDa, which lies between the molecular 
mass of dimer and trimer of Api-42 (Fig. 4-6 F). We also confirmed that the solution 
obtained by incubation of Apl-42 for 1-3 days at 37 °C under acidic conditions only 
contains well-structured Apl-42 fibrils (diameter = 3-4 nm) (Fig. 4-6E), with a very high 
ThT-signal (Fig. 4-6 D) and a characteristic P-sheet spectra in CD with a minimum at 215 
nm (Fig. 4-6 B). SEC analysis indicated that most of the peptide was blocked by the filter 
at the top of the SEC column. Finally, the protocol developed to produce ADDLs (18h 
incubation in PBS, pH 7.4, at 4°C) actually resulted in a solution containing 2-3 nm 
aggregates and no evidence of fibrils or protofibrils. SEC highlighted the presence of a 
second minor peak appearing in the SEC void volume (>75 kDa) (Fig. 4-6 F), although the 
majority of the peptide is still in its initial state (Hepler et al., 2006). The small, but 
significant, ThT signal as well as CD spectra suggests that the few oligomers contain a 
similar structural motive like amyloid fibrils.
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Fig. 4-6: Characterization of different species of native A pi-42 by AFM, CD, ThT, and SEC:
The acid solution of the depsi-peptide was switched to native APi_42 by raising the pH to > 10.5 for 15 
min at 25°C. This solution was either: i) transferred to ice and used within 2h (initial state, blue); ii) 
diluted in 50 mM phosphate buffer pH 7.4 containing 150 mM NaCI to give 100 pM peptide and 
incubated at 4°C for 18 h (oligomers, green) or iii) diluted to give 100 pM peptide in 30 mM HC1 (pH 
2) and incubated at 37°C for 3 days (Fibrils, red). Panel A, C, E: AFM analysis, the solutions were 
diluted to 10 pM in water, put on freshly cleaved mica and left there for 30 sec (fibrils) or 5 min. 
Samples were then washed with water, dried under N2 and analyzed. Panel B: CD studies peptide 
solutions were diluted to a final concentration of 20pM and analyzed at 37°C. Panel D: ThT 
fluorescence was measured after addition of 50pM ThT to a solution containing 1 pM peptide (final 
concentration). The value for the “oligomeric” preparation was significantly different from that of 
the preparation at its initial state (p<0.05). Panel F: SEC, each peptide solution was injected at a 
final concentration of 20 pM.
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Recently, it was proposed that the cellular prion protein (PrP ) is the Ap oligomer-receptor 
mediating Ap-induced synaptic dysfunction (Lauren et al., 2009). Specifically, 
Ap oligomers, prepared following the ADDL formation protocol but at a higher 
temperature (22°C), in hereafter following called 22°C oligomers, bound to PrP on the 
neuronal surface and inhibited long term potentiation (LTP) in hippocampal slices of wild- 
type (Prnp+I+) but not PrP knockout (Prnp0/0) mice. SEC indicated that, in this type of 
oligomer, most peptide was converted to high-molecular-weight aggregates (>75kDa; Fig.
4-7 A), which are spherical species and protofibrils confirmed by AFM (Fig. 4-7 B).
initial state 
22°C oligomer 24 h
Time (minutes)
Fig. 4-7: AFM and SEC of Apl-42 22°C oligomers.
Panel A: SEC (running buffer 20 mM PB pH 7.4) of 20 pM off 22°C oligomer (green) and 20 pM 
initial state (blue). Panel B: AFM picture of the 22°C oligomer preparation (scan size 2 pm x 2 pm).
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SPR showed that species present in the initial state and 22°C-oligomers solution of Api-42 
bind to the monoclonal antibody 6E10, which has an affinity to amino acid residues 1-17 
of human p amyloid peptide, but did not bind to the pre-fibrillar oligomers detecting anti 
body A l 1 (Kayed et al., 2007; Kayed et al., 2003).
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Fig. 4-8 Binding of Apl-42 monomers and 22°C oligomers to immobilised anti-bodies 6E10 and A ll
Native stock solution samples were diluted to 1 pM in PBS and injected for 180 s and flown over the 
immobilized assemblies. Panel A: initial state. Panel B: 22°C oligomers.
The ligands can target different sites on the fibrils. To discriminate between fibril surface 
and fibril end binding we increased the amount of fibril ends by sonication. For this the 
fibrils grown under acidic condition were fragmented by a continuous ultrasound which 
was produced by a homogeniser.
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Fig. 4-9 AFM of fibrils before and after sonication
Fibrils formed under acidic condition (100 pM Api-42 at pH 2 for 15 h). Panel A: Before the 
sonication. Panel B: After the sonication with a probe containing homogenizer probe (continuous 
ultrasound for five minutes at 10% intensity).
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The ThT value of the sonicated fibrils (ThT = 198.2) were slightly higher than the un­
sonicated fibrils (ThT =190.5), indicating the binding to the fibril surface of the ligand.
4.1.5 Toxicity of the various assemblies on neuronal cells
To test the biological activity of these assemblies, we analyzed the effect of the various 
Apl-42 derived assemblies (initial state, ADDLs, 22°C oligomers, fibrils and sonicated 
fibrils) on rat hippocampal neurons grown in culture. Fully mature neurons (24 days) were 
treated with mixtures of Api-42 assemblies at various concentration and incubated for 
24 h. Fig. 4-10 A shows the concentration dependant cell toxicity of the initial state, 
ADDLs and 22°C oligomer solution. All show a similar IC50 of around 1 pM. The toxicity 
increased dramatically when the cells were treated with sonicated fibrils (IC50 around 
0.02 pM) whereas the unsonicated fibrils only show a small deviation from the untreated 
sample, but more importantly no concentration dependence (Fig. 4-10 B).
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Fig. 4-10: Concentration dependent cell viability neuronal cells after treatment with various A pl-42  
assemblies for 24h compared to the cells treated only with the buffer.
Hippocampus neuronal cells o f rat pups were put on 96-wells plate and treated with p-amyloid 
peptides derived assemblies when neurons were mature and differentiated. Cell viability was then 
analysed by the MTT-assay. Panel A: cell viability of initial state, ADDLs, 22°C oligomers. Panel B: 
cell viability of fibrils (prepared under acidic condition) and sonicated fibrils.
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4.2 Kinetics offibril formation
The nucleated polymerization (NP) and nucleated conformational change (NCC) is 
characterised by an initial lag phase, followed by a progressive increase to a final plateau 
(Harper and Lansbury, 1997; Serio et al., 2000). The observed kinetic process depends 
strongly on the reproducibility of the initial state preparation and requires the total removal 
of seeds from the stock solution. Previously, it was shown that the use of depsi-peptides 
improved the reproducibility and eased the preparation of the aggregation prone Ap 
peptides. In this chapter we will demonstrate that the depsi-peptides are a valuable tool for 
the study of the kinetics of fibril formation of Ap peptides.
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4.2.1 Sedimentation of aggregated assemblies during the CD experiments interfere 
with the secondary structure measurements under non agitating (quiescent) 
condition
First we investigated the kinetics of fibril formation of Api-40 under quiescent condition. 
For this, 50 fiM of Api-40 in PB pH 7.4 at 37°C was prepared and divided to incubate one 
part in a 1.5 ml Eppendorf vial for ThT and AFM measurements and the other part in a 0.1 
cm cuvette to determine the secondary structure by CD. We found that the overall CD 
intensity decreased without a visible formation of P-sheet structure (Fig. 4-11 A). 
Nevertheless, ThT (Fig. 4-11 D) measurement and AFM (Fig. 4-11 E) demonstrated that 
after a lag phase of 100 h, the fibril formation initiated until a plateau was reached after 
around 150 h. We hypothesised that sedimentation of aggregates could be the cause of this 
observation. This was confirmed by a decrease of the absorbance value at 214 nm which 
started at the end of the lag phase (Fig. 4-11 B). The secondary structure was followed 
throughout the decrease in absorbance (Fig. 4-11 C) and the spectra were normalised based 
on the modified values of the concentration. This should give an indication of the structure 
of the soluble species. As Fig. 4-11 C shows, the secondary structure represents mainly a 
statistical coil structure, similar to the initial state, with a minor increase in the negative 
intensity at 215 nm which is an indication for P-sheet formation. This could be due to the 
formation of oligomeric P-sheet containing assemblies, since the size of spherical 
aggregates observed by AFM increase over the 50 h time period (Fig. 4-11 E). Additional 
evidence that sedimentation is the reason for the low amount of detected P-sheet containing 
assemblies was seen by moving (shaking) the cuvette several times to ensure the 
homogenization of the solution. Fig. 4-11 A shows a significant increase in intensity at the 
negative band at 215 nm and the absorbance value increased slightly (Fig. 4-11 B). 
Nevertheless, the absorbance shows an overall decrease from that at the beginning of the 
incubation.
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Fig. 4-11: Kinetics of fibril formation of Apl-40 under quiescent condition.
50 pM of Apl-40 in 50 mM PB pH 7.4 were incubated at 37°C under quiescent condition. Panel A: 
changes in the CD spectra during the incubation; red dashed spectrum was measured after the 
homogenization of the solution. Panel B: timecourse of absorbance measurements; red triangle 
characterizes the value after the homogenization of the solution. Panel C: determination of 
normalized spectra based on the changes in concentration; red dashed spectrum was measured after 
the homogenization of the solution. Panel D: Timecourse of fibril formation monitored by ThT. 
Panel E: AFM pictures of the peptide solution at different time points (marked in red in the ThT 
trace).
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4.2.2 Kinetics of aggregation of Apl-42 and the impact of the variation in 
concentration
The more aggregation prone Api-42 behaves similar like Api-40. During the incubation of 
Api-42 in PB pH 7.4 at 37°C under quiescent condition, aggregated assemblies tend to 
sediment during the incubation in a cuvette (Fig. 4-12 A). Nevertheless the increase in the 
negative band at 215 nm in the beginning of the incubation clearly demonstrated the 
formation of soluble p-sheet aggregates. The arrest of the intensity change at 215 nm after 
25 h suggests the production of sedimentable p-sheet aggregates (Fig. 4-12 B). The 
movement after 280 h of the solution in the cuvette gave a pronounced P-sheet spectra (red 
curve, Fig. 4-12 A). The incubation of the same solution in a vial left for aggregation at RT 
(22°C) and followed by ThT measurements showed that, after a lag phase of 70 h and the 
exponential growth of ThT-sensitive species until 150 h after the start of the incubation the 
final plateau is reached (Fig. 4-12 C). Interesting is the fact that ThT sensitive assemblies 
are present even during the lag phase. Since the kinetics of aggregation is concentration- 
dependent we wanted to find conditions which permit us to study the kinetics in a 
reasonable time but still representing the features of NP (nucleated polymerization). We 
found that by increasing the peptide concentration to 100 pM, the peptide readily forms P- 
sheet species as demonstrated by the immediate increase in the CD signal at 215 nm (Fig. 
4-12 D).
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Fig. 4-12: The kinetics of fibril formation of A p i-42  under quiescent condition.
Panel A  and B: 25 pM of A p l-42  in 50 mM PB pH 7.4 were incubated at 37°C under quiescent 
condition in C D  cuvette. Panel A: changes in the C D  spectra during the incubation; red dashed 
spectrum was measured after the homogenization of the solution. Panel B: timecourse of C D  value at 
215 nm; red open box characterizes the value after the homogenization. Panel C: 25 pM of A p i-42  in 
50 mM PB pH 7.4 were incubated at 22°C  under quiescent condition in Eppendorf vial. Panel D: 
concentration dependant changes of the C D  value at 215 nm. A p i-42  was incubated in 50 mM PB 
pH 7.4 at 37°C in cuvette under quiescent condition.
78
Results
4.2.3 Stirring-induced alignment of amyloid fibrils revealed by CD
Since high concentration reduces the lag phase in the CD experiment and peptides tend to
sediment under quiescent condition, low peptide concentration and stirring could be the 
appropriate answer to the problem. To test this we incubated 3 pM of Apl-42 in a 1 cm 
cuvette under continuous stirring at 1330 rpm. We found that under this condition the lag 
phase is about 70 h and the plateau is reached after 100 h (Fig. 4-13 A). However, the final 
spectra did not resemble a typical p-sheet spectrum (Fig. 4-13 B). The shape of the CD 
spectrum does not compare to any secondary structure spectra possible. We hypothesised 
that this is due to a stirring-induced alignment of the fibrils (Adachi et al., 2007). This was 
confirmed after we switched off the stirring apparatus. Under this condition we obtained a 
spectrum which showed a pronounced P-sheet secondary structure (Fig. 4-13 C). Fibrils 
formed under this condition immediately align even at the lowest possible stirring velocity 
(Fig. 4-13 D). Turbulent stirring was tried to avoid the alignment, but this led to the 
formation of visible aggregates or precipitate (data not shown).
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Fig. 4-13: Stirring induced alignment of p-sheet assemblies determined by CD.
The changes in the secondary structure 3 pM of Api-42 in 5 mM PB pH 7.4 at 37°C was followed by 
CD by incubating the solution in a 1 cm cuvette under continuous stirring at 1330 rpm. Panel A: The 
timecourse of the CD value at 215 nm. Panel B: The changes in CD spectra during the timecourse of 
aggregation. Panel C: comparison between the spectra with and without stirring of the solution at 
the end of the incubation period. Panel D: CD value at 215 nm in dependence of the stirring velocity 
in rpm.
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4.2.4 Determination of optimal condition for the kinetic experiments
In addition to the concentration and temperature dependence of the kinetics of fibril
formation, the pH can also influence the kinetics. As demonstrated in 4.1.4, Apl-42 
exclusively forms fibrils at acidic pH. Preliminary data suggested that, at neutral pH the lag 
phase is absent at high peptide concentration (data not shown). However, at low peptide 
concentration, the peptide undergoes an unordered coil to p-sheet transition with an iso- 
dichroic point at 206 nm observed by CD spectroscopy (Fig. 4-14 A). Fig. 4-14 B shows 
the time-course of this transition, investigated at either 25°C or 37°C. A lag phase of about 
5 hours was apparent at the lower temperature, whereas it significantly decreased to < 2h at 
37°C. The results were highly reproducible as shown by the very low SD values obtained 
from the results of three different experiments. Additionally, an increase in temperature 
augmented the velocity of the rate of fibril elongation (Fig. 4-14 B).
Following the changes of ThT fluorescence during the incubation of Ap peptides on a plate 
reader with periodical shaking is another popular technique (Hortschansky et al., 2005; 
Klement et al., 2007). We demonstrated that 10 pM Api-42 aggregates faster than 50 pM 
Api-40 under the same condition (Fig. 4-14 C). The single experiment was done in 
triplicate and the small SD in the half time of aggregation, which was 27.5 h and 16.2 h for 
Api-40 and Api-42 respectively, again proved the high reproducibility (Fig. 4-14 D).
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Fig. 4-14: Optimised kinetics of Fibril formation of A(31-42 and Api-40.
Panel A: Api-42 readily forms p-sheet-containing species. A pl-42 stock solution was diluted in 
acidic buffer (Stenhagen buffer, pH 2.5) to 20 pM and incubated at 25°C. CD spectra were obtained 
every 20 min. The blue trace was taken at t=0 h and the red trace at t=20 h. The transition to p-sheet 
is associated with the increase of the negative value at 215 nm. Panel B: Kinetics of formation of p- 
sheet containing Apl-42 species at pH 2.5; effect of temperature. Data at 37°C are means±SD of the 
results from three independent experiments. Panel C: Kinetics of fibril formation of A pi-40/ Api-42  
(50/10 pM) incubated on a plate reader in 50 mM PB pH 7.4 at 37°C. Polymerization was 
accelerated by periodical plate shaking every 10 min. Panel D: Halftime of transition. Data are 
means±SD of three traces of the same experiment.
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4.2.5 Analysis of Apl-42 fibril elongation by Surface Plasmon Resonance
Probing the binding of Ap monomers to preformed fibrils by SPR gives valuable insights
into the elongation phase of the kinetics of aggregation. For these studies we immobilised 
Api-42 fibrils, either sonicated or not, on the sensor chip. Api-42 monomers were 
immobilised in parallel as internal control whereas a sensor surface was left empty for 
referencing. No decay of the SPR signal was observed when flowing buffer for 30 min 
over just-immobilised Apl-42 fibrils (data not shown) indicating that no depolymerisation 
occurred at variance with the slow linear decay observed with immobilised Api-40 fibrils 
(Cannon et al., 2004). Fig. 4-15 shows the results obtained by injecting three different 
concentrations of Apl-42 monomers (1-3-10 pM). No binding was observed during the 
flow of Api-42 monomers on the reference, empty, surfaces (not shown). Apl-42 
monomers showed a marked and dose-dependent binding to fibrils - but not to monomers -  
which under our experimental conditions never reached plateau. Very good reproducibility 
was observed when repeating peptide injections over the same sensor surface without 
intermediate regeneration steps (see the replicates in Fig. 4-15).
Fig. 4-15: A pi-42 fibril elongation investigated by SPR:
Apl-42 monomers, fibrils and sonicated fibrils (from left to right) were immobilized on three 
parallel strips of the same sensor chip, with similar immobilization levels. Figures show the 
corresponding sensorgrams, i.e. time course of the SPR signal expressed in Resonance Units (1 RU = 
1 pg protein/mm2), each of them normalized to a baseline value of 0. As regards A pi-42 monomers, 
the black and grey sensorgrams indicate the results o f two consecutive injections without any 
intermediate regeneration step. These sensorgrams could be fitted well according to the 
conformational change model.
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The multiphase dissociation could be well fitted by a triple exponential function, with a 
plateau indicating that a significant fraction of the binding is likely irreversible. These 
features are consistent with the dock-and-lock model of fibril elongation (Esler et al., 
2000), in which the “locking” step is due to sequential conformational changes, each 
increasing the affinity of the monomer for the fibril until a condition of irreversible binding 
is reached. Accordingly, the sensorgrams could be adequately fitted by a complex equation 
modelling the “dock-and-lock” mechanism (“conformational change” or “three steps” 
model), as previously described for Apl-40 (Cannon, Williams et al. 2004). The results of 
this analysis are shown in Table 4-2 and indicate that the initial binding step between Apl- 
42 monomers and Api-42 fibrils has an apparent Kd of 44 pM.
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Fig. 4-16 Global fitting of the sensorgrams obtained injecting Apl-42 monomers (three concentrations)
over immobilised A pi-42 fibrils:
Representative sensorgrams obtained in a single run, injecting the three concentrations of APi.42 
monomers at the same time. The three sensorgrams were analyzed together (i.e. global fitting) using 
the nonlinear least squares data analysis program CLAMP (Myszka and Morton 1998) and using a 
three-step conformational change model (Cannon, Williams et al. 2004). The fittings are shown in 
red.
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Table 4-2: The kinetic parameters obtained in three independent runs, identical to the one shown here, 
are indicated in Table. The table reports the mean±SD of the kinetic parameters in three independent 
runs. The data for Api_40 are from Cannon et al. (16) and are shown here for comparison.
APi-42 APi_40
k, (M'1 S'1) 9.1 ± 1.3 x 103 6.6 ± 1 .5  x 103
k., (s_1) 4.0 ± 1.9 x 10_1 8.1 ± 1 .4  x 1 0 1
k2 (s*1) 4.7 ± 1.9x10-2 6.4 ± 0 .4  x10-2
k2 (s-1) 2.9 ± 0.6 x 10'3 4.4 ± 0 .4  x10-3
k3 (s-1) 4.4 ± 0 .2 x 1 0 3 4.6 ± 0 .2  X10-3
k 3 (s-1) 5.9 ± 0.8 x 10-4 4.3 ± 0 .3  x 10"*
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4.2.6 Investigation of the kinetics of aggregation of a guest-host system Apl4-24 
permits the incubation at neutral pH under quiescent condition
Since reasonable results of the kinetics of fibril formation of Api-42 using CD under 
quiescent was so far only obtained at acidic pH, we wanted to have smaller Ap fragment 
which showed similar features of nucleated polymerisation at neutral pH, similar to the full 
length sequence at acidic pH. Recently Camus et al. described a guest-host peptide that can 
be used for in vitro mechanistic and screening studies aimed at discovering aggregation 
inhibitors that target highly amyloidogenic sequences (Camus et al., 2008).
ir Af'St- t^*MOKtVFFAeOV-@-LC-f.i 2 2
° / \r ^ m  HQKLVfTAEOV 5 ? )
4-17: Design principles of host-guest switch-peptides that are derived from AP14-24 (guest) which 
contains two switch elements at the N and C termini, separating the guest sequence form the p-sheet 
formation favouring host sequence (SL-motif)(Camus et al., 2008).
We also prepared the guest-host peptide containing the hydrophobic core of Ap residues 
14-24 with click elements (depsi-bond) at the N and C termini to investigate the usability 
as a reliable tool to design kinetic experiments of high reproducibility at neutral pH.
After dissolving the peptide in 10 mM PB pH 7.4 at 37°C to give 172 pM, the peptide 
secondary structure of the initial state is mainly in random state. Nevertheless, under these 
conditions (neutral pH), the native sequence of the peptide is formed and the aggregation is 
triggered which is characterised by a random to p-sheet transition with an apparent iso- 
dichroic point at 209 nm (Fig. 4-18 A). The iso-dichroic point disappears during the 
progression of polymerization, the final spectrum is not a pure in p-sheet secondary 
structure and a loss in overall intensity in the CD spectrum is visible. This is again due the 
sedimentation of ordered aggregates which is indicated by the fact that after an initial 
increase (light scattering), the absorbance value at 214 nm decreases (sedimentation) (Fig. 
4-18 B) and the CD intensity at 214 nm reaches a plateau which represents only the 
structure of the soluble species in the solution.
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Nevertheless, the highly reproducible kinetic data (Fig. 4-18 C) show a characteristic lag 
phase which is with 0.6 h three times smaller at 37°C compared to 25°C (Fig. 4-18 C). 
Decreasing the peptide concentration from 176 pM to 82 pM extended the lag phase from 
2°h to 8 h at 25°C (Fig. 4-18 E).
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Fig. 4-18: The kinetics of fibril formation of Api4-24:
A pi4-24 peptide powder was dissolved in 10 mM PB pH 7.4 put into a 0.1 cm cuvette. Panel A: CD 
spectra of the random structure to p-sheet transition of 172 pM Ap at 37°C. Panel B: timecourse of 
the transition from Panel A, monitoring CD signal at 214 nm and its corresponding absorbance 
values. Panel C: Reproducibility of the kinetics run in triplicate under the same condition as in 
Panel A. Panel D: timecourse of the transition at different 25°C and 37°C. Panel E: timecourse of the 
transition at 86 uM and 172 uM at 25°C.
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To further investigate the properties of the model peptide, we determined the aggregate 
induced change in the ThT signal during the incubation in PB pH 7.4 at 22°C and the 
structures formed in the end of the polymerization. The aggregates are short, needle-like 
and fibrillar (Fig. 4-19 A), and the characteristic ThT fluorescence develops at the end of 
the transition (60 minutes: Fig. 4-19 B). Aggregates formed during the lag phase are ThT 
sensitive and the characteristic fibril elongation with a final plateau is observed.
Fig. 4-19: The kinetics of fibril formation of Apl4-24: AFM and ThT.
Fibril formation of 86°pM AP14-24 peptide in 10 mM PB pH 7.4 incubated at 37°C. Panel A: AFM 
picture in the end of the transition (10x10 pm). Panel B: Changes of the ThT during incubation.
This model peptide is subsequently used to investigate the changes to the lag phase and 
initial kinetics of fibril formation in the presence o f anti-amyloidogenic compounds by CD.
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4.2.7 Differences in the aggregation propensity of Api-40 MUT (A2V) compared to 
Api-40 WT
The finding that the A2V mutation in the Ap fragment of APP strongly boosts Ap 
production (Di Fede et al., 2009) raises the question if only the higher amount of Ap 
peptides is responsible for the early onset of the disease in patient. We set out to 
investigate the kinetics of aggregation to clarify this point. Theoretical consideration based 
on the software tool Zyggregator and mutational studies suggested that the mutation at 
position two increased the fibrillar and the generic aggregation propensity (Kim and Hecht, 
2008; Meinhardt et al., 2007).
The kinetics of aggregation was followed by in-situ ThT experiments using a plate reader. 
We confirmed that the mutation A2V in the Ap sequence greatly enhanced the rate of fibril 
formation. Fig. 4-20 A shows the two traces of the transition of 50 pM Apl-40 WT/MUT 
in PB pH 7.4 at 37°C. The length of the lag phase is around 25 h for AP1-40WT and 12 h 
for Api-40MUT but the elongation rate is similar for both variants (Fig. 4-20 A) and 
mainly long unbranched fibrils are present in the MUT sample after the transition (Fig. 
4-20 B).
Furthermore, kinetic studies confirmed the usefulness of the cut-off filtration of the 
aqueous 0.02% TFA Ap stock solution since the values for the halftime of transition 
increased and the SD values decreased (Fig. 4-20 C), which underlines the relevance of the 
removal of preformed aggregates during storage and peptide work up after the synthesis. 
This has to be done for sequences which are thought to be less prone to aggregate Api- 
40WT and even more for sequence with higher aggregation propensity like Apl-40MUT 
or Apl-42.
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Data Zoom
Fig. 4-20: In-situ ThT kinetics of fibril formation of 50 pM A pi-40 WT/MUT in 50 rnM PB pH 7.4 at 
37 °C.
1: H eight 10.0 pm
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Samples were shaken every 10 min and done in triplicate. Panel A: The time dependent changes in 
ThT values during the incubation of Api-40 WT (blue) and Api-40 MUT (red). Panel B: AFM scan 
of Api-40 MUT in the end of the transition (10x10 um scan). Panel C: The halftime of transition of 
Ap 1-40WT and Ap 1-40MUT before and after the cut-off filtration (10 kDa).
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4.3 Tetracycline and the synthetic Ap fragments
In this chapter, the previous findings are examined in the light of the interaction with TCs 
of the various assemblies and the influence on the kinetics of fibril formation of the 
different Ap fragments. We concentrated our investigation on TC and DC since these are 
the derivatives that have been mainly used in in-vitro studies (Bartolini et al., 2007; Forloni 
et al., 2001; Howlett et al., 1999a; Inbar et al., 2008; Ono and Yamada, 2006).
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4.3.1 Solubility of TC and the changes of the CD spectra depending on the pH
Many molecules have been proposed to exhibit an anti-amyloidogenic effect (Necula et al.,
2007b). For most of them the mechanism of action is unknown. Recently, for some of the 
compounds, a unifying mechanism of compound self aggregation was proposed (Feng et 
al., 2008). These compound aggregates are thought to be localised to preformed fibrils and 
prevented new fibril formation by a possible non-specific interaction with the monomer 
(Lendel et al., 2009). The formation of these colloids was tested by centrifugation and flow 
cytometry which resulted in the determination of critical aggregation concentrations (Coan 
and Shoichet, 2008). Since TCs are amphiphilic in nature (Forloni et al., 2009) we 
determined the absorbance of TC after centrifugation of various concentration of TC in PB 
pH 7.4 at 22°C. After centrifugation at 16 000 g for 1 h the absorbance of the supernatant 
were measured. Fig. 4-21 shows that the linearity breaks down after the concentration 
reaches 2 mM, which is much higher than any concentration used to demonstrate the anti- 
amyloidogenic effect and could determine the solubility limit of the compound under this 
condition.
0.1
0.01
concentration [mM]
Fig. 4-21: The solubility of TC.
50 mg of TC was diluted in 1 ml of water. This solution was diluted to give up-to 50 mM in 50 mM 
PB pH 7.4 to give various concentrations. The sample was left for 1 h in the dark at 22°C. After the 
samples were centrifuged for 1 h at 16000g, the supernatant was taken and the absorbance was 
determined at 360 nm.
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The CD technique will be extensively used to investigate the kinetics of fibril formation in 
presence of various compounds. However, the TCs show a pronounced optical activity in 
the wavelength region for peptide secondary structure determination. In addition the 
absorbance spectra changes depending on the pH of solution (Schmitt and Schneider, 
2006). We wanted to know to what extend pH influences the CD spectra of the TCs DC. 
Fig. 4-22 A and B show the high pH dependency of the CD spectra, and the corresponding 
absorbance spectra.
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Fig. 4-22: pH dependent changes in Doxycycline CD spectrum and absorbance spectrum.
20 pM DC was dissolved in 20 mM of 500 ml Stenhagen buffer initially at pH 2. The pH value was 
monitored with pH meter. The pH (2-12) was changed with a 0.1 M HC1 solution by 0.25 pH units. 2 
ml of this solution was put in a 1 cm cuvette and the CD spectra were taken. The red curve indicates 
the spectra at pH 7.4. Panel A: CD spectra. Panel B: absorbance spectra.
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4.3.2 Binding of tetracycline to Ap fibrils
Since TC has been reported to bind the fibrils with an EC50 of 8.7 pM (Inbar et al., 2008), 
we used SPR, CD and fluorescence spectroscopy to investigate the binding of TC to 
preformed fibrils. The fibrils were prepared under acidic condition and immobilised on the 
SPR chip or diluted to 10 pM for the CD and fluorescence measurements in PB pH 7.4 at 
25°C. None of three methods showed evidence of binding (Fig. 4-23). First we wanted to 
detect any changes in the CD spectra due to binding of TC to fibrils, but no deviation from 
the linear concentration-dependent increase of the CD value at 288 nm was observed over 
a large concentration range. The SPR was used to investigate interaction of the compound 
with immobilised species. First the compound was injected for 180 s at various 
concentrations (data not shown). Since this was not successful, the compound was flowed 
constantly with the running buffer over the various species. But even under this condition 
TC didn’t show any binding capability (Fig. 4-23 C). The sensitivity of SPR was 
determined to be sufficient since, in a corresponding experiment CR (Congo Red) showed 
a binding curve with apparent Kd of 4.5 pM (Fig. 4-23 D) to fibrils. Moreover CR 
demonstrated its high selectivity for amyloidogenic structures since it didn’t bind to 
ADDLs and monomers Fig. 4-23 D). Unexpectedly, ThT did not show the usual 
association curve during the injection and dissociation curve during the dissociation. Only 
a fast increase and decrease of the signal was observed (Fig. 4-23 E) which is characteristic 
for a bulk effect due to the variation of the refraction index of the solution in the presence 
of the compound or due to electrostatic interaction. A similar picture is drawn by 
fluorescence spectroscopy. TC does not show specific features which are indicative of 
fluorescence changes upon binding. Moreover the fluorescent variant of CR, X-34 and as 
expected ThT showed fluorescence emission from interaction of the dyes with species due 
to binding (Fig. 4-23 F-G).
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Fig. 4-23: Binding of TC to fibrils investigated by CD, SPR and fluorescence spectroscopy.
Panels A, B: Titration experiment; A bl-42 fibrils prepared under acidic condition were diluted to 10 
pM into 50 mM of PB pH 7.4 and the CD spectra was measured for varying TC concentrations. 
Panel B: concentration dependant changes of the CD signal at 288 nm. Panel C: 30 pM TC in PBS 
was flown for 30 min over immobilized fibrils and monomers. Panel D: 3 pM CR to the immobilized 
species (fibrils, sonicated fibrils, monomers). Panel E: 100 pM ThT in PBS were injected to bind to 
immobilized fibrils 180 s. Panel F-H: Fluorescence spectroscopy (20x) of 15 pM fibrils in 50 inM PB 
pH 7.4 buffer containing 100 pM TC (F) X-34 (G) and ThT (H).
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4.3.3 Tetracycline and the kinetics of fibril formation
Since no apparent binding was measured, we examined if TC is able to alter the kinetics of 
aggregation. For this following experimental set-ups were used: 1. in-situ ThT on plate 
reader (Api-40 in PB pH 7.4 at 37°C in presence of varying concentration of TC) 2. 
Changes of CD signal at 215 nm during the aggregation of Guest-Host-System Ap 14-24 in 
the presence of 300 pM TC and DC in PB pH 7.4 at 37°C and 3. Changes of CD signal at 
215 nm during the aggregation of Api-42 in the presence of 100 pM TC in 50 mM 
Stenhagen buffer pH 2.5 at 25°C.
In all three experiments no change of the lag phase and elongation rate was observed (Fig. 
4-24). Only the final plateau in the in-situ ThT experiment decreased with increasing 
compound concentration (Fig. 4-24 A). But no difference in kinetic parameter are observed 
after the normalization of the traces to the final value under the assumption that most of the 
monomer is polymerised and the differences in the final value is due to different ThT 
sensitive structural motives. Moreover, the kinetics of random to P-sheet secondary 
structure was not altered based on the invariance of the kinetic traces in the CD 
experiments compared to the control under neutral (Fig. 4-24 C) and acidic condition (Fig. 
4-24 C). To investigate the elongation rate of monomers to fibrils, which was shown to be 
varied in the presence of TC, we determined the binding curve of monomers to preformed 
(sonicated) fibrils immobilised on a SPR chip in the presence of 100 pM TC. An important 
feature of the experimental design is the fact that the compound was already present in the 
running buffer before the monomer was injected to ensure the saturation of potential 
binding sites (even that no binding was seen in the previous binding studies, see 4.3.2). 
Nevertheless, Fig. 4-24 E confirms that the elongation rate is not altered in presence of TC.
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Fig. 4-24 TCs and the kinetics of fibril formation.
Panel A: In-situ ThT kinetic of 100 pM Apl-40 in 50 mM PB pH 7.4 at 37°C without and in presence 
of 250 pM or 500 pM TC done in triplicate. Panel B: Normalized date of Panel A. Panel C: CD 
transition monitored at 215 nm of 172 pM A(?14-24 in 50 mM PB pH 7.4 at 37°C without and in 
presence o f 300 pM TC or 300 pM DC. Panel D: CD transition monitored at 215 nm of 20 pM A pi- 
42 in 50 mM Stenhagen buffer 2.5 at 25°C without and in presence of 100 pM TC. Panel E: fibrils 
and sonicated fibrils were immobilized on an SPR chip and 100 pM TC constantly flown over. 
10 pM of A pl-42 initial state solution in PBS were injected and the results were compared to results 
obtained without the presence of TC in the running buffer (see 4.2.5).
98
Results
4.3.4 Stability of Tetracycline
TCs are known to be unstable under various condition which is mainly covered by pH 
(neutral to basic) and temperature (Durckheimer, 1975). The extent to which these interfere 
with the values obtained by in-situ ThT and CD during the kinetics of fibril formation is 
subject of this section. The changes of the CD and absorbance spectra of TC at neutral pH 
in PB at 37°C were investigated. Under these conditions a significant decrease of the 
absorbance value in the BCD ring characteristic band is observed (Fig. 4-25 A). The 
changes are even larger for the CD spectra where nearly all the characteristic features are 
lost (Fig. 4-25 B). It has to be noted that during the decomposition the absorbance at 
wavelength higher than 430 nm and at least up to 500 nm increased. The process takes 
about 60 h at 37°C and accelerated by increasing temperature to 20 h or 2 h at 60°C or 
90°C respectively (Fig. 4-25 C ).
Recently it was argued that destabilizing reaction could be catalyzed by proteins as well 
(Necula et al., 2007b). We confirmed that the presence of 100 pM Apl-40 in PB pH 7.4 at 
37°C destabilised 250 pM RTC to a greater extent than a solution only containing the 
compound (Fig. 4-25 D).
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Fig. 4-25: The decomposition of TC.
Panel A: Changes in the absorbance spectra of 700 pM TC in 50 mM PB pH 7.4 at 37°C (blue trace 
= initial spectrum, red trace = final spectrum). Panel B: Changes in the CD spectra of TC under 
condition like in Panel A (blue trace = initial spectrum, red trace = final spectrum). Panel C: Loss of 
CD signal at 295 nm due to the decomposition of TC during the incubation under the same condition 
like in Panel A only the temperature was varied. Panel D: Kinetic experiment similar to the in-situ 
ThT experiment only ThT was not present. The changes o f the absorbance value at 500 nm due to 
the decomposition of 250 pM RTC were determined without and in presence of 100 pM Apl-40 in 50 
mM PB pH 7.4 at 37°C.
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4.3.5 The influence of the Tetracycline instability upon CD and ThT measurements
This site reaction makes it extremely difficult to interpret kinetic data. Fig. 4-26 shows the
absorbance change at 500 nm during the time course of the kinetic of 100 pM Apl-40 in 
PB pH 7.4 at 37°C without and in presence of 250 pM RTC. As already mentioned, the 
absorbance value changes immediately due to the decomposition of RTC. Nevertheless, 
the lag phase is unchanged compared to the control experiment (arrow Fig. 4-26).
-0.002-1---------- 1---------- 1---------- 1---------- 1---------- r
0 10 20 30 40 50
T im e [h]
Fig. 4-26: Turbidity changes at 500 nm of Api-40 during fibril formation in either presence of absence 
of RTC.
100 pM A pi-40 were incubated in 50 mM PB pH 7.4 with and without the presence of 250 pM RTC. 
The conditions are the same as for the in-situ ThT experiments except that no ThT was added to the 
solution.
How does the decomposition influence the outcome the kinetic results? Since the
decomposed TC exhibits a significant absorbance increase at the ThT specific 482 nm
emission wavelength (Fig. 4-27 A), we were concerned that these effect could interfere
with the results of the ThT measurement. We used preformed fibrils prepared under acidic
condition and determined the ThT value by varying the concentration of fresh or
decomposed TC. Fig. 4-27 B clearly shows that decomposed TC lowers the ThT value in a
concentration dependent manner with an EC50 of 3.7 pM whereas fresh TC leaves the
ThT-value nearly unchanged. That this decrease is not due to the disaggregation of the
fibrils was demonstrated by the use of a peptide (fibril) free glycerine/50 mM PB pH 7.4
system which increases the ThT fluorescence at 482 nm similar to that observed to amyloid
bound ThT because of the high viscosity of the solution (Stsiapura et al., 2008). Fig.
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4-27 C confirmed that decomposed TC reduces the ThT fluorescence at higher 
concentration whereas the effect by fresh TC is not so pronounced. CD, the other used 
technique to study the kinetics of fibril formation is influenced as well. Fig. 4-27 D shows 
the changes in the CD signal at 215 nm during the decomposition of TC in PB pH 7.4. The 
values are up to 20 h relatively stable and increase thereafter. Nevertheless the presence of 
TC in the solution increases the noise level. This finding suggests that the duration of ThT 
and CD kinetic experiments should not exceed 10 h or 20 h respectively.
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Fig. 4-27: The decomposed TC influences the ThT fluorescence and the CD measurement.
Panel A: The change of the absorbance value at 482 nm during the incubation of 700 pM TC in 50 
mM PB pH 7.4 at 37°C. Panel B: Fluorescence measurement of fibrils (prepared under acidic 
condition) at varying concentration of fresh and decomposed TC in 50 mM PB pH 7.4. Panel C: 
Fluorescence measurement of fibrils (prepared under acidic condition) at varying concentration of 
fresh and decomposed TC in 50:50 Glycerine/50 mM PB pH 7.4. Panel D: The change of the CD 
value at 215 nm during the incubation of 700 pM TC in 50 mM PB pH 7.4 at 37°C.
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4.3.6 No disaggregation of preformed aggregates
Several publications reported that TC is able to disaggregate preformed fibrils (Forloni et 
al., 2001). This was mainly done by EM and ThT measurements (Forloni et al., 2001; Ono 
et al., 2006b). Here we investigated the changes of the CD value at 215 nm and the ThT 
value upon incubation of amyloid containing samples in the presence of 300 pM TC in PB 
pH 7.4 at 37°C. In one experiment, 50 pM of Apl-42 fibrils (prepared under acidic 
conditions) and in another 50 pM Api-42 aggregates (22°C oligomers) were incubated for 
up to 10 h in the presence of 300 pM TC. No changes in CD and ThT intensity were 
observed over this period of time (Fig. 4-29).
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Fig. 4-28: No disaggregation of fibrils and 22°C oligomers by CD and ThT.
Fibrils prepared under acidic condition were diluted into 50 mM PB pH 7.4 to give 30 pM Apl-42  
fibrils which were incubated in the presence of 300 pM TC at 37°C. Panel A: Time course of CD 
values at 215 nm. Panel B: ThT value of samples from the solution in Panel A;
22°C oligomers were diluted into 50 mM PB pH 7.4 to give 30 pM Apl-42 fibrils which were 
incubated in the presence of 300 pM TC at 37°C. Panel C: Time course of CD values at 215 nm. 
Panel D: ThT value of samples from the solution in Panel C.
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4.3.7 DC does not reduce the plaque load in an animal model
Recently it was shown that DC is capable of disrupting TTR CR-positive amyloid deposits 
and decreases standard markers associated with fibrillar deposition in a transgenic mouse 
model for mimicking the transthyretin amyloid deposition in-vivo (Cardoso and Saraiva, 
2006). To study the effect of DC on amyloid deposits in-vivo, we used Ap fragment 
overproducing APP/PSltg mice whose phenotype shows a greatly enhanced formation of 
plaques compared to normal APP mice (Fig. 4-29 E). After 15 month of plaque deposition, 
the mice were treated with DC or with physiological solution for 15 weeks. The amount of 
plaques, which were estimated by investigation of immunostained brain slices, did not 
show any reduction of the deposits in treated mice (Fig. 4-29 A, C) compared to the control 
mice (Fig. 4-29 B, D).
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Fig. 4-29: No differences in amyloid plaque deposition after doxycycline treatment of APP/PSltg mice.
15 month old APP/PSltg were treated with 10 mg/kg DC or physiological solution for 20 days, after 
this the mice were sacrificed and the brains were removed, brain slices prepared and stained with 
6E10 antibody and immonostained. Panel A, C: untreated. Panel B, D: treated animals. Panel E: 
normal mouse brain.
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The studies in literature investigating the effect of TC as anti-amyloidogenic compound are 
not consistent. Whereas some in-vitro studies by ThT fluorescence, EM spectroscopy and 
CD suggested that low concentrations of the compound reduce the formation of amyloid 
during incubation (Bartolini et al., 2007; Forloni et al., 2001; Hamaguchi et al., 2006) or 
disaggregate fibrils (Forloni et al., 2001; Hamaguchi et al., 2006), other studies did not see 
a pronounced effect under similar conditions (Gellermann et al., 2006; Howlett et al., 
1999a). To clarify this discrepancy this project has further investigated the effect of TC 
upon binding to carefully characterised and well-defined preformed assemblies of various 
Ap related model peptides, and possible effects on the kinetics of fibril formation.
5.2 Refinement ofpeptide preparations for kinetics offibril formation
The importance of the preparation of reliable stock solution of self aggregating peptides is
well known (O'Nuallain et al., 2006; Teplow et al., 2006). Initial studies using Apl-40 
synthesised by classic peptide synthesis showed a great variability in the initial state 
secondary structure (Fig. 4-1 A), as monitored by the concentration-independent ratio 
between the CD values at 205 and 215 nm (Fig. 4-1 B). This was due to the requirement 
for extensive vortexing during peptide solubilisation (Fig. 4-1 C) and could be reduced by 
adding AcN as a co-solvent during peptide dissolution (Fig. 4-1 D) as suggested by 
Bartolini et al. (Bartolini et al., 2007). However, AcN also induces changes in secondary 
structure which in turn alter the kinetics of fibril formation (Bartolini et al., 2007). The 
highly soluble depsi-peptides, which are stable under acidic condition, (Coin et al., 2007; 
Dos Santos et al., 2005; Sohma and Kiso, 2006), have proven to be a valuable alternative, 
since the peptide powder readily solubilises without extensive vortexing (Fig. 4-1 D). 
Normally the native sequence is obtained by O-N acyl migration (“click”) at neutral pH at 
room temperature in 2 h  (Sohma et al., 2005). This can be reduced to 15min if the 
temperature is increased to 37°C (Taniguchi et al., 2009). This is not always applicable, 
since published protocols especially for the formation of Apl-42 oligomers (ADDLs) and
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fibrils (acidic pH) require high peptide concentration (Dahlgren et al., 2002) which would 
induce immediate rapid p-sheet formation at neutral pH (Fig. 4-12 D). A mixture of 5 mM 
NaOH and 15 mM ammonium aqueous solution clicked the peptide in less than 15 min 
(Fig. 4-5 F). Unwanted hydrolysis of the ester bond is reduced under these conditions and 
the purity of the converted peptide exceeds 95% (Fig. 4-5 C), and should give a 
homogeneous monomeric state (Fezoui et al., 2000). But even the high solubility of the 
depsi-peptide and the low aggregation propensity (e.g. normally Apl-42 forms readily 
fibrils under acidic condition) did not exclude the formation of some ThT sensitive 
aggregates during work-up and storage of the peptide powder (Fig. 4-1 D). This could be 
due to intermolecular p-sheet formation especially between the C-termini of Apl-42 
monomers (Tuchscherer et al., 2007). These aggregates were removed by cut-off filtration 
(lOkDa) of the depsi-peptide stock solution (un-converted peptide). The sequence- 
dependent loss of material was highest for more aggregation prone peptide Apl-42 (50 %) 
(Fig. 4-1 E). By comparison more than 90 % of the material was lost when the stock 
solution of the native peptide was filtered which could be due to oligomeric assemblies at 
basic pH (Bourhim et al., 2007). The presence of seeds in the untreated stock solution is 
further confirmed by the longer lag phase and the lower variability in the halftime of 
transition after the stock solution was filtered through a cut-off filter (Fig. 4-20 C) 
(Bieschke et al., 2008).
The reliable preparation of the stock solution using the depsi-peptide approach permitted 
the comparison of various peptide assemblies derived from Ap fragments (initial state of 
Api-40 compared to Apl-42 (Fig. 4-3 A) or Apl-40 compared to Api-40 (A2V) mutation 
(Fig. 4-4 A)). The initial secondary structure state for all investigated Ap fragments is 
mainly a statistical coil which conforms to literature data (Table 7-1). The two additional 
amino acids in Api-42 increased slightly the p-sheet content. But no detectable changes in 
secondary structure were determined in a new mutation in the unordered N-terminus
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(A2V) compared to the WT sequence (Di Fede et al., 2009) which was also supported by 
the identical shape of the secondary structure spectrum of the N-terminus hexapeptide (Fig. 
4-4 B). Nevertheless the A2V mutation increased the propensity to aggregate (Di Fede et 
al., 2009; Kim and Hecht, 2008) as indicated by reduced lag phase in the in-situ ThT 
experiment (Fig. 4-20 A). This could be due to the higher hydrophobicity or P-sheet 
forming propensity of Valine over Alanine (Fig. 7-4). The binding of monomers to the 
structured nucleus is possibly governed by region other than the N-terminus (e.g. 
hydrophobic core), since binding of monomers of both variants to immobilised WT fibrils 
did not show any differences (Di Fede et al., 2009). Interestingly the elongation rates for 
both variants are similar in the in-situ ThT experiment. In NP the rate of fibril nucleation 
(lag phase) is the product of the monomer and nucleus concentration and the rate of fibril 
elongation is proportional to the monomer concentration (Powers and Powers, 2006). Since 
the lag phase is shorter in the MUT variant more oligomers should be present in the 
solution and hence should provide more sites for monomer addition and consequently 
should increase the rate compared to the WT peptide. Nevertheless, the models used to 
describe the aggregation kinetics of MUT and WT do not have to be the same. Due to the 
higher hydrophobicity favourable unordered aggregates could be formed which later 
reorganise to the more ordered amyloid structure (Auer et al., 2008; Cheon et al., 2007). 
Another influencing parameter is fibril fragmentation which was shown to dictate the rate 
of fibril elongation during agitation of p2-microglobulin on a plate reader (Xue et al.,
2008) and could be the major process which deviates the rate from expected values.
The immediate formation of Api-42 p-sheet structure at high peptide concentration (Fig. 
4-12 D) could be an indication for lower energy barrier for monomer addition to the very 
first oligomers in solution (Auer et al., 2008). The monomer addition to fibrils of Api-42 
can be described by the NCC derived “Dock and Lock”. Like Api-40 (Cannon et al., 2004) 
and PrP82-146 (Gobbi et al., 2006), the model described the binding data of monomers to
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fibrils immobilised on a SPR chip (Fig. 4-16). The initial binding step between Api-42 
monomers and Apl-42 fibrils has 2.9 times lower Kd than that previously reported using 
Apl-40 (123 pM) (Cannon et al., 2004) , mainly because of a 2-times slower dissociation 
rate constant (Table 4-2). The following conformational changes appeared not to be 
different between the two peptides.
5.2 Preformed assemblies and toxicity
We further characterised different assemblies of the Apl-42 peptide using protocols 
developed in this work (cut-off filtration of depsi-peptide and switching under slight basic 
condition, see section 7.3) or in the literature. This allowed preparation of different 
solution like initial state solution (immediately after dissolution of the basic stock solution 
in the buffer of interest), oligomers (Ap derived diffusible ligands or ADDLs, (Lambert et 
al., 1998)), 22°C oligomers (Lauren et al., 2009) or fibrils (Stine et al., 2003). Results from 
physical-chemical experiments using the depsi-peptide approach (Fig. 4-6) strongly 
confirmed that the peptide is at its very initial state, possibly in the form of monomers 
(Hepler et al., 2006), although our data do not allow to exclude the presence of very small 
unstable oligomers in dynamic equilibrium with monomers (Bernstein et al., 2009; Bitan et 
al., 2003a; Rangachari et al., 2007). Interestingly the behaviour between fibrils and 
oligomers (ADDLs and 22°C oligomers) differed in SEC analysis. Most of the fibrils were 
blocked by the filter at the top of the SEC column, whereas ADDLs and 22°C oligomers 
show a second peak appearing in the SEC void volume which is greatly enhanced in the 
22°C oligomers (Fig. 4-6 F) and which further correlated with the increase in ThT 
fluorescence (Fig. 4-28 D). This finding suggests that ADDLs and 22°C oligomers 
constitute a ThT sensitive p-sheet like state, as suggested by others (Finder and 
Glockshuber, 2007; Glabe, 2008). Recent data further support the toxic role of p-sheet 
assemblies which could be dimer up to tetramer in the case of Api-40 (Ono et al., 2009). 
Since fibrils and oligomers are ThT sensitive, a similar structural motif could be present in
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fibrils and toxic oligomers. The variance in toxicity could depend on the size of the 
otherwise similar structure. This is supported by the fact that only sonicated fibrils but not 
fibrils by themselves show a concentration dependent toxicity (Fig. 4-10 B). Nevertheless, 
we cannot exclude that the amount of other toxic oligomeric forms is enhanced after 
sonication due to the shift in the equilibrium since more monomers could be released from 
the fibrils to form toxic oligomeric species in solution (Pastor et al., 2008). In variance 
with the literature (Pastor et al., 2008) Apl-42 initial state solution is toxic similar to the 
ADDLs or 22°C oligomers solution (Fig. 4-10 A), but less toxic than sonicated fibrils (Fig. 
4-10 B). This could be due to the rapid formation of toxic oligomers under experimental 
condition (Bitan et al., 2003a). In addition, toxic P-sheet species may be formed by 
interaction with the cellular membrane, since membrane mimicking reagents like SDS 
have been shown to induce stable toxic p-sheet oligomers (Barghom et al., 2005a; 
Rangachari et al., 2007; Yu et al., 2009). The size of these oligomers is thought to be a 
dodecamer (Bernstein et al., 2009) possibly a basic unit of various detected toxic oligomers 
like the ADDLs (Roychaudhuri et al., 2009).
5.5 TC and its binding to Ap assemblies
The methods used in this work - changes in CD values, SPR, fluorescence - investigating 
the binding of TC to the preformed fibrils were not able to detect differences compared to 
the control experiment (Fig. 4-23). Even given that SPR is sensitive enough to detect 
binding of CR or the Api-6 hexapeptide (Di Fede et al., 2009) to fibrils, TC flown over 
preformed fibrils for long period of time did not alter the signal (Fig. 4-23 C). One reason 
could be that ligands with different modes of interaction to the fibril substructure could 
bind at different sites like fibril ends, between monomers of P-sheets or the fibril core at 
varying stoichiometry. For instance CR may interact with fibrillar p-sheets in 1:1 
stoichiometric ratio of monomer (bound in the fibril) by binding to the fibril surface 
(Roterman et al., 2001) as also proposed for the Ap peptide (Carter and Chou, 1998). The
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surface binding is supported by the finding that the sensorgram in SPR of fibrils and 
sonicated fibrils are similar (Fig. 4-23 D). Nevertheless, ThT exhibiting a pronounced 
increase in fluorescence (Fig. 4-6 D) did not show binding to immobilised fibrils in SPR 
(Fig. 4-23 E). This could be explained by a low binding ratio 1:115 between the ligand and 
fibril bound monomer (LeVine, 2005) which would dramatically reduce the amount of 
compound bound to the fibril surface which is thought to be in a cavity of the fibril 
(Groenning et al., 2007). In addition, the two times lower molecular weight of ThT 
compared to CR could be responsible for the negative SPR, since under these 
circumstances the detection limit of the instrument could be reached. A low binding ratio 
could also explain the negative results in SPR experiments using TC. Inbar et al. also 
demonstrated the low amount of bound TC (Inbar et al., 2008). In this study the anti-body 
binding capability to preformed fibrils was reduced only by 20 % in the presence of TC 
with a notable low IC50 of 8.7 pM. Nevertheless, the unchanged fluorescence values 
reported in this work do not support this hypothesis, since TC can change its fluorescence 
spectrum upon binding to metal ions (Schneider et al., 2003). In the end, one question 
always stands out, since already the slightest variation in the fibril forming condition 
changes the morphology of the final aggregate (Petkova et al., 2005). “How relevant are 
these in-vitro formed structures?” Possibly the fibrils formed in this work vary in structure 
and stability compared to the aggregates formed by others (Ono and Yamada, 2006; Ono et 
al., 2003; Tagliavini et al., 2000). Nevertheless, TC has been reported to disaggregate 
fibrils derived from different peptide sequences which would suggest a more general 
mechanism. Additionally, the conditions used in other publication favour also the 
formation of off fibril pathway aggregates. The exclusive preparation of fibrils, like done 
in this work and shown by AFM and other techniques, allowed the investigation of the 
binding capability of the ligand to them.
114
Discussion
A constantly claimed mechanism of action of TCs is the disaggregation of preformed 
fibrils (Forloni et al., 2001; Ono and Yamada, 2006). We followed the changes CD 
intensity at 215 nm and ThT fluorescence of fibrils and 22°C oligomers in the presence of 
TC over a time period of 10 h (Fig. 4-28). No changes were observed. This would not 
exclude the possibility that fibrils were fragmented, as was shown to happen in case of P2- 
microglobulin fibrils in the presence of ThT as result of laser irradiation (Ozawa et al., 
2009). Nevertheless, the secondary structure is still in p-sheet and the ThT is as high as in 
the beginning of our experiment. In fact, fragmentation could induce toxicity due to the 
higher mobility of smaller species similar to the increase in toxicity of sonicated fibrils 
which could worsen the situation in-vivo (Fig. 4-10 B). Nevertheless, no reduction of the 
plaque load in an Ap over expressing mouse model is seen after DC treatment which 
suggests that no disaggregation takes place in-vivo (Fig. 4-29).
5.4 TCs and the kinetics offibril formation of Ap
Binding to fibril surface shouldn’t hinder the elongation of fibrils, especially when no 
secondary fibril growth on surface takes place. Ap fibrils are thought to be long and 
unbranched (Fig. 4-23 E) (Andersen et al., 2009), which suggests no fibril surface induced 
fibril growth. The rate of elongation was tested by following the random-coil to p-sheet 
transition by in-situ ThT and CD experiment of Api-40, Api-42 and Ap 14-24 and binding 
of monomers to Api-42 fibrils by SPR without and in presence of TC. Ap 14-24 has been 
demonstrated to be a convenient tool to test the potential of small compounds for altering 
the kinetics of aggregation (Camus et al., 2008). The model expresses the usual features of 
NP with lag phase and additional fibril growth (Fig. 4-18 C) which depend on the 
temperature and the peptide concentration (Fig. 4-18 D, E). Any change in the 
polymerization characteristic parameters (lag phase, rate of elongation, final plateau) could 
give information about the possible mechanism of action. Especially the change in the lag 
phase could indicate an interaction of the ligand with more toxic oligomers which are
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thought to be formed in the early stages of the polymerization process. Nevertheless, 
despite of the differences of the final plateau values in the in-situ ThT experiment of Apl- 
40 depending on the TC concentration, no parameter of the kinetics was altered in any 
experiment carried out to investigate the effect of TC (Fig. 4-24). Several explanations for 
the difference in the final plateau of the in-situ ThT experiment are possible. First, the 
critical concentration of fibril formation is different and more unpolymerised monomers 
are in solution which then gives also different elongation rates. Second, the variation in 
fibrillar structure might alter the binding capability of ThT which in turn gives a different 
value but leaves the critical concentration unchanged. Under this assumption we 
normalised the traces with maximum ThT value. We found no change in the parameters of 
the kinetics. Third, the compound interferes with the ThT measurements. Several recent 
studies demonstrated the insufficiency of ThT fluorescence measurements to judge the 
potential of a compound and, more important showed that small compounds like 
Rasvertrol or Rifampicin bias the ThT results (Hudson et al., 2009; Meng et al., 2008). 
Fresh TC only slightly interfered with the ThT-test (Fig. 4-27 B), but decomposed TC, 
which is easily formed at 37°C and was even enhanced by increasing temperature (Fig. 
4-25 C), reduced the ThT-value to nearly zero with a low IC50 (Fig. 4-27 B). This is 
possibly due to quenching since the absorbance of the decomposed TC increased at the 
ThT important emission wavelength at 482 nm (Fig. 4-27 A). This was confirmed in a 
fibril free high viscose aqueous glycerin solution (Fig. 4-27 C) which could be used as a 
general tool to investigate the interference of a compound with the ThT-test. The 
decomposition has an impact on the CD transition monitored at 215 nm as well, since it 
could diminish the total CD value at this wavelength (Fig. 4-27 D). Because of the 
instability of TC the incubation was restricted to 10 h. This excluded non agitated CD or 
ThT experiments together with the stirring experiments at low peptide concentration which 
gave a flow induced alignment of fibrils with a similar CD spectra seen by Linear
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Dichroism (LD) spectroscopy (Fig. 4-13) (Daffom et al., 2004) which is inverted in CD 
spectroscopy (Adachi et al., 2007). The invariance of the kinetic parameters further 
supports the finding that TC does not bind to the preformed assemblies discussed in the 
previous section.
The binding of monomers to immobilised fibrils in presence of TC probes also the 
association of TC to free monomers in solution. In aqueous solutions Ap monomers appear 
to be largely unstructured with several regions adopting weak p-strand and a-helix 
conformations (Yang and Teplow, 2008). One can speculate that helix stabilization could 
hinder the aggregation to p-sheet containing assemblies (Nerelius et al., 2009), since the 
equilibrium could shift from helical to p-sheet secondary structure during aggregation 
(Takeda and Klimov, 2009). Interesting is the fact that TC was suggested to bind to a- 
helical prion fragments (Ronga et al., 2007). Nevertheless, the unchanged aggregation rate 
in the kinetic experiments and especially the unchanged SPR sensorgrams during the fibril 
elongation in the presence of TC did not support this mechanism of action.
Only a few kinetic data concerning the fibril formation of Ap in the presence of TC are 
available in literature. A complete kinetic data set by means of a CD experiment showed 
no change of the lag phase of Apl-42 but a slower elongation rate (Bartolini et al., 2007). 
Nevertheless since the authors do not show the plateau after the transition, this change 
could also be due to a different p-sheet conformation, the decomposition of the TC during 
the experiment or the sedimentation of the aggregates. The only ThT-kinetic data available 
show a very high efficiency of reducing the fibril formation potential, fibril elongation and 
fibril destabilization by TC of the Apl-40 and Api-42 (Ono and Yamada, 2006) and a- 
synuclein (Ono et al., 2006a). In these experiments a concentration dependent reduction of 
the ThT value at the plateau is observed (Fig. 5-1A). Nevertheless the normalised traces 
are nearly super-imposable (Fig. 5-IB), thus questioning the interpretation that the kinetics 
of fibril formation is affected by the compound. Furthermore, the time period of the
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experiment was six days which could lead to false positive results due to TC
decomposition.
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Fig. 5-l:Alpha synuclein in the presence of different concentration of Tetracycline (A) original data (B) 
normalization by the final value (Ono and Yamada, 2006)
In another study, Kirschner et al. used X-ray diffraction studies to determine the variation 
of the total amount of P-crystallite, the fibril length and the fibril width in the presence of 
anti-amyloidogenic compounds (Kirschner et al., 2008). TC was tried on AP 11-25 and 
Ap 12-28. It was found that the length and the intersheet stacking of Ap 11-25 are not 
altered by the compound. Only the overall intensity (amount) is diminished (Fig. 5-2).
A = 5.70mM Abeta (11-25) and 
B = 5.70mM Abeta (11-25) + 6.93 mM TC
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Fig. 5-2: Amount of p-structure, fibril length and intersheet stacking of A p il-2 5  with and without 
Tetracycline determined by X-ray diffraction patterns (adapted from Kirschner et al. (Kirschner et al., 
2008))
In case of Ap 12-28 a concentration dependent decrease of the fibril length was observed.
Nevertheless, this study uses extreme high peptide and compound concentrations which
might produce aggregates which are not present in-vivo. Furthermore the high variability
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of the results and the missing standard deviation for the experiment in the presence of the 
compound are not satisfactory. Another caveat in the experimental setup is the use of water 
for the preparation of the fibrils and stock solutions of the compounds. Since TC 
hydrochloride is used a change in the pH of the solution can be expected which could 
affect the aggregation process.
In comparing the in vitro studies reported in this thesis with the results of in-vivo or in- 
vitro experiments on the effect of TCs reported in literature, it cannot be ruled out that TCs 
may have alternative targets, not necessarily Ap. In addition, toxic Ap species other than 
the ones investigated may provide alternative sites of TCs action. Especially, the so called 
Al 1 positive pre-fibrillar oligomers (Kayed et al., 2003) which are different to the soluble 
fibrillar oligomers (e.g. ADDLs, amylospheroids) (Kayed et al., 2007; Noguchi et al., 
2009) could not be detected under any of the experimental conditions used in this work 
(Fig. 4-8 B). For instance, it was shown that RTC inhibited the formation of Al 1 positive 
species but not the fibrillization of Apl-42 (Necula et al., 2007b). Nevertheless, RTC like 
TC is unstable and gave no reliable results from which we could draw a final conclusion 
(Fig. 4-26). It seems that the lag phase is not changed which would suggest the presence of 
only a small amount of RTC sensitive oligomers, if any, which do not change the overall 
monomer concentration significantly and hence do not alter the kinetics of fibril formation. 
Nevertheless, the relevance of Al 1 positive species can questioned since a recent study 
demonstrated that only the level of soluble fibrillar oligomers and not Al 1 positive pre- 
fibrillar oligomers correlated with the cognitive decline in transgenic mouse models 
(Tomic et al., 2009).
Finally, several studies focused on the therapeutic potential of TCs in AD suggesting that 
at least MC could act as neuroprotective agent affecting various pathways (Kim and Suh,
2009). MC reduces microgliosis, caspase-1 activity, formation of interleukin lb, 
metalloprotease activity, and production of cyclooxygenase and prostaglandins. MC has
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also been shown to reduce nitric oxide (NO) levels by inhibition of p38 activation (Lin et 
al., 2001). NOs are known to inhibit the mitochondrial respiration (Brown and Borutaite, 
2006) which is thought to play an important role of mitochondrial dysfunction in the 
pathogenesis of AD. Interesting to this concern is the fact that oligomeric and fibrillar 
species of Apl-42 impair mitochondrial function in P301L tau transgenic mice (Eckert et 
al., 2008). TC has been found to decrease NO-levels as well (D'Agostino et al., 1998). 
Furthermore, the radical scavenging potential TCs could positively influence the symptoms 
of the disease (D'Agostino et al., 1998; Kim and Suh, 2009). Thus a range of mechanism 
other than direct action on Ap species may be relevant to therapeutic application of TCs.
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Thus, in conclusion, the possibility of TCs as therapeutics for AD as related to the specific 
target of suppression of amyloid formation appears not to be supported by the experiments 
reported here. However, the challenge of producing a reproducible system of amyloid fibril 
formation, monitored by AFM and other techniques, has created new opportunities for 
physical studies of an important polymerization process. Depsi-peptides permit a reliable 
and reproducible preparation of Ap assemblies and greatly reduced the variability of a 
single kinetic experiment, which lowers the number of repetition and the amount of used 
material. The formation of the native sequence under slightly basic condition kept the 
hydrolysis of the ester bond at a minimum and allowed the preparation of the different AP 
species to investigate binding of Ap ligands like monomers or small compounds by various 
physico-chemical techniques. In this way, it was shown that, similar to Api-40, the fibril 
elongation of Api-42 follows the “Dock and Lock” mechanism and that a mutation in the 
N-terminus (A2V) enhances the kinetics of fibril formation. In future work, kinetic studies 
of these systems can be extended by a) the additional knowledge of the formation of 
different oligomeric forms suitable for seeded growth of fibrils; and b) seeded 
polymerisation could now be used to allow better definition of the kinetic parameters for 
polymerization and depolymerisation. In addition, the structural studies on Ap amyloids 
could be complemented by the preparative techniques developed here, to allow correlations 
between polymerization conditions and resultant structures to be sought under more 
controlled condition.
Care has to be taken if TCs are used in kinetic experiments, since their decomposition 
could interfere with the experimental outcome. We demonstrated for the first time that 
decomposed TC, but not fresh TC, dramatically reduced the ThT value. We propose the 
use of a fibril-free aqueous Glycerine solution to evaluate the disturbance of the ThT 
fluorescence by TCs and other compounds.
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Taking into consideration the instability of TC, it was concluded that neither binding to 
preformed assemblies nor kinetic parameters are altered by the compound under condition 
applied in these studies. Since only monomers or fibrillar aggregates (oligomer or fibril) 
were possibly present in our studies, one possible target left for further investigation is Al 1 
positive pre-fibrillar species. Nevertheless the multitude of targets of the compounds in 
various pathways of the brain could contribute even more to the positive effect of TCs in 
animal studies and might be also worth investigating.
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7.7 Secondary structure of Ap related fragments determined by various 
techniques
Table 7-1: List o f publication concerning the determination of the secondary structure of various Ap 
fragments
Sequence Structure/conformation Experimental conditions Methods reference
AM -40 Cross-0 water FD (Malinchik 
et al., 1998)
AM -28 Fibrillar, cross-0 aqueous EM, FD (Kirschner et 
al., 1986)
AMO-35 0-sheet (parallel), in register PH 3.7 or pH 7.4 STEM, ssNMR (Antzutkin 
et al., 2002)
AM -42 0-sheet, in-register parallel Aqueous, pH 7.4 EM, STEM, 
ssNMR
(Talafous et 
al., 1994)
AM -28 a-helix, bend at 12 Membrane mimic, SDS and 
TFE
NMR (Talafous et 
al., 1994)
AM -40 1-10, disordered; 12-24 and 30- 
40, 0-strand; 25-29, a bend
Aqueous, pH 7.4 x-ray, EM, 
ssNMR
(Petkova et 
al., 2002)
AM -28 Random coil Water (pHl-4) CD (Barrow and
Zagorski,
1991)
AM-28 a-helix; increased temperature 
leads to decrease in helix, 13-20 
remain most stable helix
TFE (4-7) NMR (Barrow and
Zagorski,
1991)
A M -39 Random coil and 0-sheet Aqueous (pH 7.3) CD (Barrow and
Zagorski,
1991)
AM-39 a-helix TFE (30%) (pH 1-4, 7-10) CD (Barrow and
Zagorski,
1991)
AM -42 0-sheet water CD (Barrow and
Zagorski,
1991)
AM -40 a-helix 10-24 and 28-42 SDS (pH 7.2) NMR (Shao et al., 
1999)
AO 1-42 a-helix 10-24 and 28-42 SDS (pH 7.2) NMR (Shao et al., 
1999)
AO 1-28 a-helix; increased temperature 
leads to decrease in helix, 13-20 
remain most stable helix
TFE (4-7) NMR (Zagorski 
and Barrow, 
1992)
A01-28 0-sheet Water (pH4-7) CD (Zagorski 
and Barrow, 
1992)
AO 1-28 Not a-helical, extended strand Water (pH5.6) NMR (Lee et al., 
1995)
AO 1-28 C-terminal a-helix, N-terminal 
turn (flexible)
DMSO NMR (Sorimachi 
and Craik, 
1994)
A01-39 0-sheet (60%) Aqueous (pH 7.4) CD (Shen and
Murphy,
1995)
AO 12-28 a-helix 16-24 SDS (pH2.6) NMR (Fletcher 
and Keire, 
1997)
AO 10-23 0-sheet (antiparallel) Solid state FTIR (Hilbichet 
al., 1991)
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AMO-43 80% 13-sheet Water CD (Hilbich et 
al., 1991)
AMO-43 28% a-helix HFIP CD (Hilbich et 
al., 1991)
A1325-35 13-sheet PH5.5, pH 7.4 AJ329-42 
13-sheet (antiparallel)
Solid state FTIR (Hilbich et 
al., 1991)
AJ325-35 13-sheet Aqueous (pH 7.4) CD (Hilbich et 
al., 1991)
AMO-35 13-sheet (parallel), in register Dried from water (pH 7.4) ssNMR (Benzinger 
et al., 1998)
AMO-35 13-sheet (parallel), in register Dried from water (pH 7.4) ssNMR (Benzinger 
et al., 1998)
AMO-35 13-sheet (parallel), in register Dried from water (pH 7.4) ssNMR (Burkoth et 
al., 2000)
AM 6-22 13-sheets (antiparallel) 1.0 mM phosphate buffer, 
pH 7.0 EM,
ssNMR (Balbach et 
al., 2000)
A1325-35 13-sheet > random coil (decreased 
concentration)
Aqueous (pH4, 5) CD (Terzi et al., 
1994)
A1334-42 13-sheet (antiparallel) aqueous FTIR, ssNMR (Lansbury et 
al., 1995)
AM -40 a-helix 15-36, kink 25-27 SDS (pH 5.1) NMR (Coles et al., 
1998)
AM -40 a-helix 15-23, 31-35 TFE (40%) (pH 2.8) NMR (Sticht et al., 
1995)
AM -40 13-sheet (parallel, in-register) Aqueous (pH 7.4) ssNMR (Antzutkin 
et al., 2000)
AM -40 13-sheet (parallel, in-register), 
residue 1-9 without structure
PBS (140 mM NaCl, 3 mM 
KC1, 10 mM phosphate, pH 
7.4)
ssNMR (Balbach et 
al., 2002)
AM -42 13-sheet 18-26, 31-42(parallel, in­
register)
10 mM TRIS (150 mM 
NaCl, pD 7.7)
HDex-NMR (Luhrs et al., 
2005)
A fill-25 P-sheet antiparallel (register pH 
dependent and differs to A016- 
22); ssNMR and X-ray 
inconsistent
aqueous pH 7.4, 2.4 ssNMR, X-ray (Petkova et 
al., 2004)
AM -40 Quaternary structure o f fibrils MD, theor. X- 
ray
(Buchete et 
al., 2005)
AM -40 Quaternary structure o f fibrils ssNMR (Petkova et 
al., 2005)
AM -40 Random state o f the initial 
solution
PB (pH 7.4) CD (Bieschke et 
al., 2008)
AM -42 Random state to P-sheet 
transition
PB (pH 7.4) + low amount 
of AcN
CD (Bartolini et 
al., 2007)
AM -40/42 Random state o f the initial 
solution
PB (pH 7.4) CD (Rangachari 
et al., 2007; 
Rangachari 
et al., 2006)
AM -40/42 a to p sheet transition PB (pH 7.4) + SDS CD (Rangachari 
et al., 2007; 
Rangachari 
et al., 2006)
AM -40 Random state o f the initial 
solution
PB (pH 7.4) CD (Gursky and 
Aleshkov,
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AM -40
AB 1-9 
AB 1-16 
AB 1-28 
AB 12-28 
AB 16-21 
A61-40 
AB 25-35
AB 1-40/42
Random state o f the initial 
solution
Random state o f the initial 
solution
Anti-parallel P-sheet o f the 
initial solution
Random state o f the initial 
solution
Borate buffer (pH 9) 
PB (pH 7.4)
PB (pH 7.4) 
PB (pH 7.4)
CD
CD
CD
CD
2000)
(Klement et 
al., 2007) 
(Danielsson 
et al., 2005)
(Danielsson 
et al., 2005)
(Macao et 
al., 2008)
127
Appendix
7.2 Chemistry of solid state peptide synthesis (adapted from (Kirin et al,, 
2007)
7.2.1 Fmoc deprotection
Fmoc-Aaa1-Wang-resin
H-Aaai-Wang-res!n
Fig. 7-1: Mechanism by arrow pushing of the removal of the Fmoc Na-protecting group.
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7.2.2 Amino acid coupling
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DIPEA
Fmoc-HN
Fmoc-HN TBTU
Fmoc-Aaa-OH
Fmoc-HN
Fmoc-HN
activa ted  am ino acid
H-A aat-W ang-resin
Fmoc-HN
Fm oc-A aaa-A aai-W ang-resin
Fig. 7-2: Mechanism by arrow pushing of the coupling reaction using TBTU in the presence of DIEA.
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7.2.3 Final deprotection from the resin and side chain deprotection
Appendix
HN
marker
HN C - C H 3
o \  c h 3 h ^ ; c h 3 
h S ch> h
Fig. 7-3: Mechanism by arrow pushing of deprotection reaction of tBu and cleavage of a peptide from
Wang resin.
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7.3 Initial state and sample preparation
7.3.1 Preparation of stock solutions of Depsi-Apl-40/1-42
Depsi Ap was dissolved in an acidic solution (TFA 0.02%, pH <3) at a concentration of 
about 1 mg/ml and centrifuged through a 10 kDa cut-off filter (YM-10, Millipore) at 
14000g. The filter was washed two times by addition of same acidic solution and the 
centrifugation step was repeated. The loss of material using this procedure is around 40%. 
The final concentration of Ap in the filtered solution was determined with UV-absorption, 
using the theoretical molar extinction coefficient at 280 nm (1490 M'1 cm'1) (Pace et al., 
1995) or at 214 nm like suggested by Kuipers et al. (Kuipers and Gruppen, 2007). Final 
concentration of Depsi Api-42 was usually higher than 90 pM. This stock solution was 
flash frozen in dry ice/ethanol and stored at -80°C. These samples were used within 
2 weeks.
7.3.2 Formation of native Ap and sample preparations
The filtered acidic stock solution was concentrated with a 3 kDa cut off filter (YM-3, 
Millipore) to around 300 pM. Then, the native sequence was obtained by adding 0.5 M 
NaOH:ammonium (1:3) solution on ice to give a pH >10.5. This solution was diluted to 
1 pM in PBS and used immediately (“initial state solution”). To prepare Apl-42 fibrils, the 
stock solution was diluted with water to 100 pM Ap, acidified to pH 2.0 with 1 M HC1 and 
left for 24 h at 37°C (Stine et al., 2003). To obtain Apl-42 oligomers, the stock solution 
was diluted to have 100 pM peptide in 50 mM phosphate buffer, 150 mM NaCl, pH 7.4, 
and incubated for 24 h at 4°C(Lambert et al., 1998).
131
Appendix
7.4 The sequence dependant properties which influence the aggregation of 
the Ap mutation (A2V) compared to the WT sequence
Fig. 7-4: The amino acid dependant hydrophobicity, p-sheet propensity, contribution to a hydrophilic, 
hydrophobic pattern and a-helix propensity; Alanine (WT) and Valine (MUT) are highlighted.
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